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Abstract: Breast cancer is one of the leading causes of cancer‐related morbidity and mortality in
women worldwide. Early diagnosis and effective treatment of all types of cancers are crucial for a
positive prognosis. Patients with small tumor sizes at the time of their diagnosis have a significantly
higher survival rate and a significantly reduced probability of the cancer being fatal. Therefore,
many novel technologies are being developed for early detection of primary tumors, as well as dis‐
tant metastases and recurrent disease, for effective breast cancer management. Theranostics has
emerged as a new paradigm for the simultaneous diagnosis, imaging, and treatment of cancers. It
has the potential to provide timely and improved patient care via personalized therapy. In nan‐
otheranostics, cell‐specific targeting moieties, imaging agents, and therapeutic agents can be em‐
bedded within a single formulation for effective treatment. In this review, we will highlight the
different diagnosis techniques and treatment strategies for breast cancer management and explore
recent advances in breast cancer theranostics. Our main focus will be to summarize recent trends
and technologies in breast cancer diagnosis and treatment as reported in recent research papers and
patents and discuss future perspectives for effective breast cancer therapy.
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1. Introduction
Breast cancer has a very long history as it was first reported by the ancient Egyptians
more than 3500 years ago in about 1500 B.C [1]. Today, breast cancer is the second most
prevalent type of cancer and is a leading cause of most cancer‐related deaths in women
in the United States [2]. Around 281,550 women are projected to be diagnosed with breast
cancer in 2021, and 43,600 women are predicted to die due to breast cancer in the US,
according to the American Cancer Society. Early diagnosis of the disease is crucial for
effective treatment and positive prognosis, as significantly lower probability of dying and
higher survival rate is observed in patients with smaller tumors at the time of diagnosis
[3]. Early detection of breast cancer and accurate lesion assessment are, therefore, the pri‐
mary focus of all imaging modalities. At present the two major pillars to be addressed for
effective management of breast cancer disease include: (i) diagnosis of breast cancer in its
earliest stages and (ii) providing timely treatment after diagnosis to save lives.
Imaging of the breast is utilized almost exclusively for detection, diagnosis, and clin‐
ical management of cancers and for the assessment of the integrity of breast implants (Fig‐
ure 1) [4]. As a conventional medical imaging modality, ultrasound has played a key role
in breast cancer detection, image‐guided biopsy, and lymph‐node diagnosis for many
years. Mammography, ultrasonography, magnetic resonance imaging (MRI), scintimam‐
mography, single photon emission computed tomography (SPECT), and positron
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emission tomography (PET) are other commonly used imaging modalities [5–7]. Based on
the diagnosis and assessment of the extent of breast cancer, the need for preoperative (ne‐
oadjuvant) systemic therapy is determined. Targeted and effective therapies with minimal
off‐target side effects are needed for breast cancer treatment. As breast cancer is a global
problem, major emphasis also needs to be put on diminishing worldwide disparities in
terms of access to diagnosis, multimodal treatment, and novel drugs.

Figure 1. Representation of the various imaging techniques that can be used in breast cancer diagnosis.

For this review, we conducted a literature search within the Google Scholar and Pub‐
Med databases using the keywords: “Breast Cancer”, “Imaging”, and “Treatment” in the
title field, with dates from 2000 to 2021. After reading the abstracts, we manually selected
the relevant papers for this review. In this review article, we examine various detection
techniques for breast cancer, provide an in‐depth analysis on the therapies for different
subtypes of breast cancer, and investigate recent trends and the future of breast cancer
theranostics.
2. Techniques for Diagnosis or Detection of Breast Cancer
Early diagnosis is a key to successful breast cancer treatment. T1 tumors measuring
less than 2 cm in diameter have a 10‐year survival of approximately 85%, while T3 tu‐
mors—essentially the result of delayed diagnosis—have a 10‐year survival of less than
60% [8]. Imaging techniques commonly used for detection of breast cancer are summa‐
rized in Table 1.
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Table 1. Summary of various imaging modalities for screening of breast cancer.
Imaging Modality

Principle

Mammography
(First‐line tool for breast
screening)

Low‐dose ionizing x‐
ray creates detailed
images of the breast.

Uses low‐energy ra‐
dio waves and strong
Magnetic Resonance Imag‐ magnets to obtain de‐
ing
tailed images of
structures within the
breast

Employs magnetic
Magnetic Resonance Spec‐ field on body fluids
troscopy
and tissue samples to
obtain chemical infor‐
mation of that region

Dynamic Contrast En‐
hanced MRI (DCE‐MRI)

Multiple MRI scans
taken post i.v. injec‐
tion of contrast agent

Diffusion‐Weighted Imag‐
ing

Employs diffusion of
water molecules to
generate contrast.

Diagnostic Accuracy

Advantages

Limitations
Uses ionizing radia‐
tion.
Sensitivity decreases
with increasing breast
Most cost‐effective.
density.
Good response with
Sensitivity: 75–90%
Accuracy is low in
high specificity and sen‐
Specificity: 90–95%
young women.
sitivity.
Spatial Resolution: 50 µm
High false‐positive
Portable device.
results in young
women due to dense
breasts.
Poor contrast com‐
pared to MRI.
Expensive,
inability to standard‐
ize the test.
Ability to detect breast
Unnecessary breast
Sensitivity: 75–100%
malignancies that often
biopsies due to ina‐
Specificity: 83–98.4%
escape from clinical,
bility to distinguish
Spatial Resolution: 25–100 µm mammograms, and ul‐
between malignant
trasound detection.
and benign lesions.

Overcomes limitations
Expensive and time‐
of mammography.
consuming.
Radiation‐free imaging
Low specificity.
Sensitivity: 93%
technology.
Not portable.
Specificity: 70%
Excellent Sensitivity.
False‐positive results
Spatial Resolution: up to 0.25
Excellent spatial resolu‐
in some benign tu‐
cm3
tion.
mors.
All imaging planes pos‐
sible.
False‐negative results
Sensitivity: 89–99%
Exhibits good perfor‐ observed due to arti‐
Specificity: 37–86%
mance in monitoring re‐ facts based on bleed‐
Spatial Resolution: 25–100 µm sponse post therapy. ing and tumor struc‐
ture.
Failure to detect high
Sensitivity: 83%
water content malig‐
Non‐radioactive imag‐
Specificity: 84%
nant lesions due to
ing technique
Spatial Resolution: 25–100 µm
high apparent diffu‐
sion coefficients.

Dynamic elasticity
imaging technique
that combines MRI
Non‐invasive, non‐ion‐
imaging with low fre‐
Sensitivity: 90–100%
Lacking in spatial res‐
izing and cross‐sectional
MR Elastography (MRE)
quency.
Specificity: 37–80%
olution and detection
imaging modality
Employs mechanical Spatial Resolution: 25–100 µm
of small focal lesions.
waves to create an
elastogram to assess
tissue stiffness.
Non‐invasive.
Provides twice the diag‐
Combines nuclear
nostic benefits (Elevated
Positron Emission Tomog‐ medicine technique
High‐cost.
Sensitivity: 90–100%
activity within the body
raphy conjugated with com‐ and computed to‐
Unable to detect tu‐
Specificity: 75–90%
detected by PET scan
puted Tomography (PET‐ mography resulting
mors less than 8 mm.
Spatial Resolution: 2–10 mm
and intricate images of
CT)
in high detailed im‐
tissues and organs by
ages.
CT scan).

References

[9–12]

[13,14]

[15–18]

[14,19–21]

[14,22]

[14,23,24]

[14,23]
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Not useful for pa‐
Surgical procedure to
Sensitivity: 90.5%
Significantly reduces tients with locally ad‐
Sentinel lymph node biopsy detect spreading of
Specificity: 85.7%
post‐operative compli‐ vanced cancers and
(SLNB)
cancer in lymphatic Spatial Resolution: Not Appli‐
cations
inflammatory breast
system.
cable
cancer.
Employs use of a ra‐
Able to identify smaller High radiation dose.
Sensitivity: 90–96%
Breast Specific Gamma Im‐
diotracer.
lesions (<1 cm)
Specificity: 71–80%
Not suited for routine
aging
Image captured using
Spatial Resolution: >7mm
tumor screening.
a special camera.
Accessible, real‐time le‐ Failure to detect mi‐
Employs sound
Sensitivity: 80–89%
sion visualization, cost‐ crocalcifications, pos‐
Ultrasound
waves to image
Specificity: 34–88%
effective, patient com‐ sibility of false‐posi‐
breast tissues
Spatial Resolution: 50–500 µm
pliant.
tives.

[24,25]

[26–28]

[14,29,30]

2.1. Mammography
A mammogram is an x‐ray of the breast that can reveal benign or malignant abnor‐
malities. It is obtained by applying a small dose of radiation through the breast post com‐
pression between two plates to produce an x‐ray image. Mammograms can be utilized for
both screening and diagnosis [31]. Mammogram screening is performed as an attempt to
detect any early signs of breast cancer, even before symptoms occur, to decrease mortality
by early diagnosis. Diagnostic mammogram assists in detecting breast cancer if a woman
experiences symptoms, for instance, a lump that can be felt in her breast [32]. In 2009, new
mammography screening guidelines were issued by the U.S. Preventive Services Task
Force (USPSTF) with a recommendation that routine screening mammography for
women under age 50 is not needed, whereas its earlier stance was in accordance with
American Cancer Society guidelines, which recommended mammography every one to
two years for all women age 40 and older [31–34]. In addition, since radiologists assess
information subjectively, breast density cannot be utilized to infer the information in‐
grained in a mammogram [35]. For instance, patients may have appreciably different
mammograms, each with vastly different outcomes, but have the same breast density as‐
sessment value. In previous studies, mammography results have been used to develop
statistics related to glandular tissue volume. However, these automated methods of eval‐
uating breast density are not sufficient to predict breast cancer prevalence [36]. Recently,
gold‐based nanoformulations have shown promise in significantly enhancing the contrast
in mammographic images [37]. Mammographic density can improve the accuracy of
breast cancer risk models. More accurate risk prediction can also be achieved by a mam‐
mography‐based deep learning (DL) model [36].
2.2. Magnetic Resonance Imaging
Breast MRI is a non‐invasive and non‐ionizing diagnostic imaging tool that employs
low‐energy radio frequency waves and a magnetic field to obtain detailed images of struc‐
tures within the breast [38]. MRI can be used to measure the size of the cancer and look
for metastasized tumors in women who have been previously diagnosed with breast can‐
cer. Tumors with size less than or equal to 2 cm have been accurately identified and meas‐
ured using MRI. However, larger breast tumors are often overestimated due to the abnor‐
mal breast tissue encompassing the actual lesion, which can lead to greater mastectomy
rates [39,40]. Goldsmith et al. first described the use of nuclear MRI for the breast 40 years
ago [41]. Several uses of MRI for the breast, including screening the high‐risk population,
have been recommended by the American College of Radiology [42]. MRI has the ability
to detect suspected breast malignancies that often escape clinical, mammographic, and
ultrasound detection [37]. Fe3O4, gadolinium(III)‐, and Mn(II)‐based contrast agents are
commonly used for preoperative assessment, especially to visualize axillary lymph nodes
of the breast [43]. To reduce the possibility of off‐target toxic effects and increase specific‐
ity towards breast cancer, these contrast agents may be encapsulated within breast cancer‐
targeting polymeric carriers [44,45]. Because of the high sensitivity and lower specificity
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of breast MRI, it is widely used in breast cancer diagnostics, thus, resulting in an increase
in incidental findings. It is imperative that these findings be histologically assessed before
any surgical intervention [46,47].
2.3. Dynamic Contrast Enhanced MRI (DCE‐MRI)
Dynamic contrast‐agent‐enhanced breast MRI works by analyzing the temporal en‐
hancement pattern of a tissue following the intravenous injection of a paramagnetic con‐
trast agent. This non‐invasive imaging technique quantitatively determines the extent of
tissue vascularization, interstitial space composition, and differentiation of lesions [48].
This imaging modality is useful to depict tumor angiogenesis with overall recurrence and
overall survival of breast cancer patients [49–51]. As a result, lymph node metastasis that
occurs due to greater angiogenesis in breast cancer can also be predicted using this imag‐
ing modality. DCE‐MRI, when combined with a computer‐aided diagnosis technology,
such as texture analysis, can also be used to identify estrogen receptor positive (ER+)
breast cancer subtypes [52]. DCE‐MRI technique is non‐invasive and three‐dimensional,
which allows visualization of the extent of disease before morphological alterations and
helps to predict the overall response either before the start of therapy or early during
treatment [53,54]. Unlike mammography, DCE‐MRI is not limited by breast tissue density.
However, a central limitation of DCE‐MRI is that it is non‐specific [55].
2.4. Magnetic Resonance Elastography
Magnetic resonance elastography (MRE) can be used to obtain details on tissue me‐
chanical properties in vivo [56]. Following application of an external stress, breast MRE,
a non‐invasive, non‐ionizing, and cross‐sectional imaging modality, can quantitate the
viscoelastic properties of breast tissues [57]. Breast cancers often have a higher stiffness
due to increase in the number of cells, collagen, and proteoglycans compared to the nor‐
mal surrounding tissues and benign lesions [58,59]. Although manual palpation is com‐
monly used for routine screening of the breast, it lacks specificity and sensitivity. This is
where the limitations of manual palpation can be overcome by MRE scanning of the breast
[60–62]. While the initial results are encouraging, the most significant limitation for MRE
in breast cancer is spatial resolution and detection of small focal lesions due to the overlap
in the soft malignant tumors and stiff benign lesions elasticity ranges [63].
2.5. Diffusion‐Weighted Imaging
Diffusion‐weighted imaging (DWI) is a form of unenhanced MRI that uses the diffu‐
sion of water molecules to generate contrast in MR images to address some of the short‐
comings faced by regular breast MRI [64–66]. The potential benefits of DWI techniques
include improved differentiation of benign and malignant breast lesions and assessment
and prediction of therapeutic efficacy [67]. DWI has enabled the identification of breast
cancer particularly in dense breasts. However, the sensitivity of DWI tends to be variable
compared to contrast‐enhanced MRI [68]. Technical innovations are helping to overcome
many of the image quality issues that have limited widespread use of DWI for breast [69].
While DWI may be an accurate and nonradioactive imaging technique, it has still not
achieved its full potential. Detailed investigations and clinical trials are now warranted to
prove DWI’s ability to facilitate the diagnostic work‐up of the diseases.
2.6. Magnetic Resonance Spectroscopy
Magnetic resonance spectroscopy (MRS) can measure a chemical “spectrum” in the
region using high magnetic field strengths (typically 11–14 T) on body fluids, cell extracts,
and tissue samples, providing additional information about the chemical content in the
region [70,71]. The in vivo 1H MRS protocol with the addition of MRI procedure further
increases the overall acquisition time by approximately 10 min and has the advantage to
improve the diagnostic accuracy of clinical breast MR [72,73]. The MRS specificity has
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been reported to be approximately 88%; however, the requirement of slightly larger le‐
sions and poor sensitivity to detect total choline (tCho) (a phosphocholine metabolite ele‐
vated in breast malignancies and used as a diagnostic biomarker) signal is one of the lim‐
itations of this imaging modality [16,74,75]. There has been considerable progress on
breast MRS in the last decade; however, multiple factors can potentially limit MRS, like
optimization of analysis methods and complexity of acquisition procedures, that need to
be addressed before including this imaging modality in a clinical setting.
2.7. Positron Emission Tomography (PET) Scanning and PET in Conjunction with Computer‐
aided Tomography (CT) Scanning (PET‐CT)
Positron emission tomography (PET) imaging has been widely adopted as an im‐
portant clinical modality for oncology. Even though many types of PET radiotracers have
been developed to non‐invasively interrogate in vivo tumor metabolism, 2‐deoxy‐2‐
(18F)fluoro‐D‐glucose (FDG) is the most widely used US FDA approved PET radiotracer
that takes advantage of the enhanced glucose metabolism of cancer cells [76]. Cancerous
cells are highly proliferative and have a higher glucose metabolism rate than normal cells.
FDG PET radiotracers enter cells via the glucose transporter and are, thus, taken up in
greater amounts by tumor cells than by healthy cells [77]. FDG uptake inversely correlates
with prognosis [76–78].
PET‐CT is a combination of PET (a nuclear medicine technique) and CT that produces
highly detailed views of the body. The improved spatial resolution and sensitivity of PET
scanners dedicated to breast (positron emission mammography) has allowed its clinical
application in the study of primary tumors [79,80]. Numerous studies have shown that
hybrid imaging with 18F‐FDG PET/CT provides information about the cellular glucose up‐
take, which is elevated in malignant lesions [81–84]. Jørgensen et al. observed significantly
reduced uptake of 18F‐FDG by tumor cells following nanoparticle‐assisted photothermal
therapy, indicating that it can be effectively used as a marker to assess treatment responses
[85]. Physicians use PET‐CT studies to diagnose and stage the cancer, plan treatment, eval‐
uate the effectiveness of treatment, and manage ongoing care.
2.8. Molecular Image‐Guided Sentinel Node Biopsy
Sentinel lymph node biopsy (SLNB) is a revolutionary, minimally‐invasive method
to determine whether metastasis has occurred in early‐stage breast cancer patients. De‐
pending on the nodal metastatic status, SLNB is usually conducted to select the optimal
therapeutic approach [86]. SLNB technique is well known for its significantly reduced
post‐operative complications associated with conventional axillary lymph node dissection
[87,88]. This makes effective SLNB management key towards successful breast cancer di‐
agnosis and treatment. Accurate SLNB guidance should limit the amount of invasive pro‐
cedures needed and determine if multiple‐basin drainage is occurring through localizing
sentinel lymph nodes, thus, improving the staging accuracy in women with invasive
breast cancer [89].
2.9. Breast Specific Gamma Imaging
Breast specific gamma imaging (BSGI), a molecular breast imaging approach, is a
specialized nuclear medicine imaging test that allows detection of sub‐centimeter and
mammographically occult breast cancer with a sensitivity and specificity comparable to
MRI [26]. In BSGI, a radiotracer such as Technetium Tc99m Sestamibi is injected into the
patient’s bloodstream and the breast is visualized using a special camera [90–92]. Unlike
mammography, BSGI is unaffected by breast density [93,94]. The modern BSGI has improved
sensitivity for the detection of sub‐centimeter lesions compared to scintimammography
[95]. The major drawback of this technique is that, since the whole body gets exposed to
the radiation, it is not possible to employ this for frequent breast cancer screening [96].
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2.10. Ultrasound
Although mammography is a gold standard for breast cancer imaging, because of its
limitations regarding dense breasts, another supplementing screening tool is required. Ul‐
trasound is a supplemental tool that may be utilized to analyze some breast changes in
women with dense breast tissues, as well as suspicious areas not seen on a mammogram
[97]. Advantages of this technique include its wide availability, as well as no patient ex‐
posure to radiation. At the same time, however, it is limited by a number of factors. Most
notably, it may fail to detect microcalcifications, and it may miss some early signs of can‐
cer. Because of this limitation, this technique is not used to screen for breast cancer and is
reserved for special situations. The fusion of ultrasound with other modalities [98,99].
such as ultrasound imaging techniques and ultrasound‐guided biopsy, provides im‐
portant tools for the management of breast cancer patients. Ultrasound elastography is
now a routine noninvasive tool used to measure the consistency or hardness of the tissues
to differentiate benign and malignant breast lesions [100,101]. Contrast‐enhanced ultra‐
sound and other modalities fused with ultrasound are other tools that may be useful in
the noninvasive prediction of prognostic factors of breast cancer [102]. Complementary
high resolution ultrasound is excellent for detecting breast lesions when in expert hands
[103]. On the basis of existing literature, it was found that fusion of other modalities with
ultrasound may be an effective primary detection tool for breast lesions, particularly in
low‐ and middle‐income countries with low‐resource settings and where mammography
and other expensive techniques are not available [104].
From the literature discussed above, we can see that, although ultrasound and mam‐
mography remain the most commonly used conventional methods of diagnosing breast
cancer, other modalities such as DCE‐MRI, MRE, PET, PET‐CT, SLNB, and BSGI are now
being considered for efficient collection of data. For example, most mammography meth‐
ods can only be used to gather information about one breast, while MRI can be used to
collect data from both breasts at the same time. Use of contrast agents can also enhance
the quality of the data obtained for breast cancer diagnostics.
3. Current Treatment and Novel Therapies for Different Subtypes of Breast Cancer
Breast cancer diagnosis by breast examination, mammography, breast ultrasound,
MRI, and other imaging modalities can help identify tumors and other abnormalities in
the tissue, as described above. These imaging modalities can help find a lump, an area of
microcalcification, a suspicious area on ultrasound, or a gadolinium‐enhanced area on
MRI. Once breast cancer is identified using one of the diagnostic modalities discussed
above, immediate and rigorous treatment must be provided to remove the tumor and
prevent further spread of the cancer. One of the major challenges for breast cancer treat‐
ment is its heterogeneous nature, which affects the response to therapy [105]. By evaluat‐
ing the presence of biomarkers such as hormone receptors (HRs), excess levels of human
epidermal growth factor receptor 2 (HER2) protein, and/or extra copies of the HER2 gene
[106,107], treatments that are most effective against a particular type of breast cancer can
be determined and administered (Figure 2). Based on the upregulation of genes, there are
five main intrinsic or molecular subtypes of breast cancer:




Luminal A breast cancer is low grade, HER2– and HR+ (estrogen‐ and/or progester‐
one‐receptor positive), that has low levels of the protein Ki‐67, which are responsible
for controlling how fast cancer cells proliferate. Luminal A cancers tend to proliferate
slowly with an excellent prognosis compared to other cancers.
Luminal B breast cancer is a molecular subtype of breast cancer in which the tumors
are HR+ (progesterone‐receptor and/or estrogen‐receptor positive) and show ele‐
vated levels of the protein Ki‐67 while being either HER2– or HER2+. Luminal B can‐
cer subtype is associated with faster proliferation rate and tends to be more aggres‐
sive compared to Luminal A breast cancer, making its prognosis slightly worse [108].
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Triple‐negative/basal‐like breast cancer is HR– (estrogen‐receptor and progester‐
one‐receptor negative) and HER2–. Women with BRCA1 gene mutations are more
prone to develop this form of cancer [109].
HER2‐enriched breast cancer is a molecular subtype of breast cancer in which tumors
are HER2+ and HR– (i.e., negative for estrogen‐ and progesterone‐receptor). This
subtype is associated with a tendency to proliferate at a more rapid rate than luminal
cancers [91]. However, patients are successfully treated with drugs targeting the
HER2 protein, such as Tykerb (lapatinib), Herceptin (trastuzumab), Perjeta (per‐
tuzumab), and Enhertu (fam‐trastuzumab‐deruxtecan‐nxki) [110].
Normal‐like breast cancer is identical to luminal A cancer as it is HER2–, HR+ (estro‐
gen‐ and/or progesterone‐receptor positive) with reduced levels of the Ki‐67 protein.
The prognosis of normal‐like breast cancer is, however, slightly worse than the lu‐
minal A cancer.

Figure 2. Novel FDA‐approved targeted therapies for the treatment of molecular subtypes of breast cancer.

There are several FDA‐approved drugs currently used in the treatment of breast can‐
cer (Table 2). The prodrug tamoxifen (brand name: Nolvadex) is a partial agonist that
blocks estrogen uptake by the estrogen receptor (ER) [111,112]. Studies have shown that
the risk of ER+ breast cancer recurrence can be reduced by half with tamoxifen [113]. How‐
ever, similar to most anti‐cancer therapies, tamoxifen has known side‐effects and has been
found to be associated with a number of increased health risks, such as endometrial can‐
cer, blood clots, and stroke [114,115]. Aromatase inhibitors (AIs) block estrogen from be‐
ing produced in postmenopausal women, suppressing the conversion of androgens to es‐
trogens, thus, resulting in estrogen depletion. Three generations of AIs have been devel‐
oped. The first‐generation (e.g.: aminoglutethimide) and second‐generation AIs (e.g.,
fadrozole and vorozole) are less selective with decreased production of cortisol and
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aldosterone, in addition to aromatase. They are also poorly tolerated with limited clinical
efficacy [116]. On the other hand, third‐generation AIs (e.g.: anastrozole (brand name:
Arimidex), letrozole (brand name: Femara), and exemestane (brand name: Aromasin)) are
highly selective for the enzyme aromatase and are tolerated fairly well. As a result, they
have surpassed tamoxifen as first‐line therapy for postmenopausal women with HR+ met‐
astatic breast cancer with excellent response rates and delayed progression. AIs have ad‐
ditionally shown incremental improvement in disease‐free survival, lower local and met‐
astatic recurrence rates, and a lower incidence of contralateral breast cancer over tamoxi‐
fen [117].
Table 2. List of therapeutic drugs used in the treatment of different types of breast cancer, and their status.
Drug

Drug Class

Subtype of Breast Cancer
Treated

Status

References

1

Tamoxifen
(Brand name: Nolvadex)

Anti‐estrogen

ER‐positive breast cancer

Approved

[111–113]

2

Aminoglutethimide, Fadrozole and Vorozole

First‐ and second‐
generation AIs

ER‐positive breast cancer

Approved

[116]

3
4
5
6
7
8
9
10

Anastrozole (Brand name: Arimidex)
Letrozole (Brand name: Femara)
Exemestane (Brand name: Aromasin)
Goserelin and Leuprolide
Fulvestrant
Ribociclib (LEE011)
Palbociclib (PD0332991)
Abemaciclib (LY2835219)

Third generation AIs

ER‐positive breast cancer

Approved

[118–120]

‐
SERD Degrader

Approved
Approved
Approved
Approved
Approved

[121]
[122,123]

11

Buparlisib

LH‐RH sensitive breast cancer
Breast cancer
Epidermal growth factor
receptor 2‐negative advanced
or metastatic breast cancer
(HER2)‐negative, PIK3CA‐
mutated, advanced or
metastatic breast cancer

12

Pictilisib

13

Pilaralisib (XL147)

14

Voxtalisib

15
16

Trastuzumab (Herceptin)
Pertuzumab

17

Neratinib

18

Patritumab

19

Bevacizumab

20

Sacituzumab govitecan‐hziy

21

T‐DM1 (Kadcyla)

22

Enhertu

23

Pembrolizumab (Brand name: Keytruda)

24

Atezolizumab combination with nab‐
paclitaxel

CDK4/6 inhibitor

pan‐PI3Ki

Approved

Phase I clinical
trial
HR+/HER− advanced breast Phase I/II dose‐
PI3K inhibitor
cancer
escalation study
Phase I/II dose‐
escalation study
Approved
HER2‐overexpressing breast
mAb
cancer
Approved
advanced or metastatic HER2+
TKI
Approved
breast cancer
Preclinical
anti‐HER3 mAb
HER2+ advanced breast cancer
models
TNBC patients with germline
anti‐GF mAb
mutations/ HER2‐negative
Approved
breast cancer
Relapsed or refractory
Antibody–drug conjugate
Approved
metastatic TNBC
HER‐2 metastatic prescription
adjuvant treatment when the
Antibody–drug conjugate patient has taken neoadjuvant
Approved
treatment with trastuzumab
(Herceptin) and a taxane
HER‐2 metastatic that has
Antibody–drug conjugate
resurged and cannot be
Approved
removed surgically
metastatic TNBC or TNBC that
IgG4‐ĸ mAb
has resurged and cannot be
Approved
surgically removed
mAb

PD‐L1+ TNBC

Approved

[124–126]

[127,128]
[129,130]
[131,132]
[132]
[133–135]
[136]
[137]
[138]
[139]
[140]

[141]

[142]

[143]
[144]
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Luteinizing hormone‐releasing hormone (LH‐RH) analogs (goserelin and leuprolide)
suppress the production of hormone from the ovaries [121]. LH‐RH agonists act by pitui‐
tary desensitization and receptor downregulation, thereby suppressing gonadotrophin
release. LH‐RH exerts direct anticancer activity on malignant tissue that is independent
from the suppression of the ovarian steroid synthesis and secretion [145,146]. Fulvestrant,
a selective estrogen receptor degrader (SERD), is another drug that is suitable for breast
cancer patients refractory to previous hormonal therapy. This is the first selective ER
down regulator that is available clinically. This pure anti‐estrogen results in degradation
of ER alpha (α), has no agonistic effects, and has also demonstrated activity in tamoxifen‐
resistant breast cancer models [122]. Fulvestrant is the first SERD to enter into the clinical
arena and a suitable backbone for combination therapy with new targeted agents for en‐
docrine treatment of breast cancer. Preclinical studies have demonstrated that fulvestrant
downregulates the expression of ERα in ER+ breast cancer cell lines without decreasing
ERα gene (ESR1) transcripts along with inhibition of ER‐responsive genes [147]. Fulves‐
trant can additionally block the non‐genomic actions of estradiol on the G‐protein coupled
estrogen receptor (GPER), an alternate ER with a structure distinct from the two canonical
ERs (ERα and ERβ) that is expressed in 50–60% of breast cancer, and which has been sur‐
mised to be related to the development of resistance towards tamoxifen in ERα+ breast
cancer patients [148]. The proliferation of ER+ breast cancer cells is prevented through
these processes. Additionally fulvestrant is also effective in those cell lines that are re‐
sistant to tamoxifen [149,150]. Patient derived xenograft models of ER+ breast cancer cor‐
roborated fulvestrant’s antitumor activity. Thus, we can conclude that it is more effica‐
cious compared to tamoxifen or estrogen withdrawal [151]. Endocrine drugs work by dif‐
ferent mechanisms, and thus, they are usually used as a combinational therapy for better
anticancer efficacy. Nevertheless, there are conflicting results reported. It is generally be‐
lieved that patients with endocrine‐therapy‐naïve advanced breast cancer and those with
highly endocrine‐sensitive tumors may benefit the most from combination endocrine ther‐
apy [152–155]. Several other biomarkers have emerged as potential targets for breast can‐
cer therapy as described below.
3.1. Cyclin‐Dependent Kinases 4/6 (CDK4/6) Pathway
CDK4/6 are pivotal drivers for cell proliferation as they combine with cyclin D pro‐
teins, which regulate cell processes during the G1 phase of the cell cycle. Complete under‐
standing of this cell cycle regulation may lead to promising cancer therapies [124]. Nu‐
merous studies are being carried out to explore drugs inhibiting CDK4/6 and assess the
efficacy and drug safety for the treatment of breast cancer [156]. As a result of severe ad‐
verse events and less activity, the development of pan‐CDK inhibitor flavopiridol [157]
was subsequently discontinued, and then, highly specific inhibitors, namely, ribociclib
(LEE011), palbociclib (PD0332991), and abemaciclib (LY2835219), were extensively re‐
searched and developed [124–126]. US FDA has approved palbociclib and ribociclib for
the treatment of HR+, HER2–, or metastatic breast cancer. Recent clinical trial data suggest
that significantly improved clinical outcome of palbociclib was achieved when combined
with letrozole or fulvestrant [158–161].
3.2. Phosphoinositide 3‐kinase (PI3K) Pathway
The PI3K pathway, also called phosphatidylinositol 3‐kinases, is the most commonly
activated signaling pathway in human cancer. They are a family of enzymes that are in‐
volved in cellular functions linking oncogenes and multiple receptor classes and consti‐
tute a critical signal transduction system [162]. The phosphatidylinositol‐3‐kinase
(PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway (PI3K/AKT/mTOR path‐
way) plays a key role in cancer [126]. Pan‐PI3Ki bind to PI3K isoforms in a selective and
ATP competitive manner. The combination of PI3K inhibitors with aromatase inhibitors
has been used as second‐line treatment for HR+/HER− advanced breast cancer. A potent
and highly specific oral pan‐class I PI3K inhibitor (pan‐PI3Ki), buparlisib is currently
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under investigation in patients with a variety of solid tumors, including breast cancer
[127,128]. According to a new study, toxicities associated with buparlisib make it a poor
option for the treatment of patients with HR+, HER2– advanced breast cancer that pro‐
gressed on or after mTOR inhibitor therapy. The efficacy of the agent, however, suggests
that PI3K inhibitors, along with endocrine therapy, remain a reasonable approach in pa‐
tients with PIK3CA mutations [128].
Another pan‐PI3Ki that displays equipotent inhibition of the p110α and –δ PI3K
isoforms and less potent inhibition of p110β and –γ isoforms is pictilisib [129]. In a phase
I dose‐escalation clinical trial of 60 patients with advanced solid tumors (NCT00876109),
pictilisib was found to be overall safe in patients but with severe side‐effects, such as hy‐
perglycemia, rash, and pneumonitis [140]. Additionally, pilaralisib, also known as XL147,
is an orally bioavailable small molecule with potential antineoplastic activity [131]. XL147
selectively targets and binds reversibly to class 1 PI3Ks thereby inhibiting tumor cell pro‐
liferation within tumors that are susceptible. Tumorigenesis is often related to the activa‐
tion of the PI3K signaling pathway. In a Phase I/II dose‐escalation study, pilaralisib
(SAR245408), or voxtalisib (SAR245409), a PI3K and mammalian target of rapamycin in‐
hibitor, in combination with letrozole, was evaluated for its efficacy, safety, and pharma‐
cokinetics in HR+, HER2–, non‐steroidal AI‐refractory, recurrent, or metastatic breast can‐
cer. As compared to voxtalisib, patients who were administered with pilaralisib demon‐
strated increased glucose levels compared to those who were administered voxtalisib. In
conclusion, a limited efficacy and an acceptable safety profile in endocrine–therapy‐re‐
sistant HR+, HER2– metastatic breast cancer was observed in patients treated with
pilaralisib or voxtalisib combined with letrozole, as shown [132].
3.3. Targeting HER2+ Breast Cancers
HER2+ breast cancer (HER2+ BC) is characterized by drug resistance and a high rate
of metastasis. Targeted therapy drugs have been shown to greatly improve the prognosis
of HER2+ BC patients, but drug resistance or severe side effects have limited the clinical
application of targeted therapy drugs. Various strategies are being researched to over‐
come drug resistance and to attain a more effective treatment. The HER2 oncogene (HER2,
HER2/neu, c‐erbB‐2) is situated on chromosome‐17 [163,164], and the main function of
this oncogene is to encode transmembrane receptor tyrosine kinase [165]. Tyrosine kinase
receptors play a key role in mediating various cellular functions, such as cell motility,
proliferation, metabolism, and differentiation, that are based on cell‐to‐cell communica‐
tion [140]. These receptors consist of a singular transmembrane helix, extracellular ligand
domain and an intracellular region of a tyrosine kinase domain, juxtamembrane region,
and a carboxy terminal tail [140]. Tyrosine kinase inhibitors competitively inhibit tyrosine
phosphorylation and block tyrosine kinase enzyme activity, thus, resulting in downregu‐
lation of many cellular functions [166]. Neratinib (NERLYNX, Puma Biotechnology, Inc.,
CA, USA), an irreversible tyrosine kinase inhibitor (TKI) of HER1/HER2/HER4, has been
reported to significantly improve the 2‐year invasive disease‐free survival after
trastuzumab‐based adjuvant therapy in HER2+ BC [137]. Neratinib, in combination with
capecitabine, was approved by the US FDA on 25 February 2020 for treating patients with
advanced or metastatic HER2+ BC previously treated with two or more anti‐HER2 based
regimens in the metastatic setting. Another example of TKI is Lapatinib, which competi‐
tively inhibits ATP‐binding sites intracellularly and reversibly blocks phosphorylation of
HER1 and HER2 [167]. A phase III study of lapatinib, in combination with an anti‐neo‐
plastic drug paclitaxel, demonstrated an increase in the survival rate of patients with
HER2 metastasis breast cancer [168]. Another drug moiety, tucatinib, exhibited greater
selectivity for HER2 in a phase I study of advanced disease patients along with reduced
occurrence of diarrhea, as reported by patients that received other TKIs [169].
Compared with HER2– tumors, HER2+ BC is an aggressive subtype that demon‐
strates unique epidemiological, clinical, and prognostic differences with poor response to
standard chemotherapy regimens [170]. About 30% of breast cancer patients have been
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evaluated for the expression of HER2, which is generally recognized as a marker for inva‐
sive disease that is likely to be highly metastatic, drug resistant, and to spread rapidly
[171–173]. There has been remarkable advancements in therapies for managing HER2+ BC
in the last 20 years, specifically, targeted treatments that are HER2 expression level de‐
pendent [174]. A humanized monoclonal antibody (mAb), trastuzumab (herceptin), tar‐
geted towards the HER2 ectodomain, has demonstrated activity in HER2‐overexpressing
breast cancer patients. Trastuzumab effectively inhibited basal and induced HER2 cleav‐
age, resulting in the generation of phosphorylated p95 [171]. Another mAb, pertuzumab,
binds to a different epitope of the HER2 dimerization domain than trastuzumab, prevent‐
ing interactions with other receptors in the HER2 family that lead to cell growth inhibition
[175,176]. The direct inhibitory action on the extracellular domain of HER2 has largely
contributed to the HER2‐directed mAbs antitumor efficacy.
Patritumab, a human anti‐HER3 mAb, through inhibiting the formation of
HER2/HER3 heterodimers, has shown anticancer activity in preclinical models. It was
found to exhibit favorable efficacy and acceptable tolerability in patients with HER2+ ad‐
vanced breast cancer [138]. The pharmacokinetic profile for patritumab was determined
based on the target trough level, and efficacy was evaluated based on the overall response
rate and progression‐free survival.
3.4. Treating Triple‐Negative Breast Cancer
Triple‐negative breast cancer (TNBC) accounts for about 10–15% of all breast cancers
[177]. In TNBC, the cancer cells do not possess estrogen or progesterone receptors and
also do not produce too much of the protein HER2 [178]. As compared to other breast
cancer subtypes, TNBC is far more invasive and proliferate and spreads at a much faster
rate, and patients have limited treatment options and a worse prognosis [179,180]. Stand‐
ard chemotherapy remains the mainstay treatment for TNBC. However, metastasis and
recurrence rates are higher compared to non‐TNBC tumors [181]. Advanced TNBC pa‐
tients, when treated with carboplatin with or without a taxane drug (e.g., docetaxel),
showed better efficacy and toxicity profile compared to docetaxel. Additionally, in
germline BRCA1/2‐mutated breast cancer patients, carboplatin displayed a response rate
twice as high compared to docetaxel. This implies the importance of determining whether
breast cancer patients have BRCA1/2 mutation so that the most effective drug for first‐line
chemotherapy can be chosen [182]. TNBC has the fewest therapeutic options among all
breast cancer subtypes due to the lack of well‐defined molecular targets [181]. Identifica‐
tion of new therapeutic targets and development of effective targeted agents is, hence,
urgently needed.
Sacituzumab govitecan is the first antibody–drug conjugate approved by the US
FDA in the treatment of relapsed or refractory metastatic TNBC. It was developed by cou‐
pling a monoclonal antibody that targets anti‐trophoblast cell‐surface antigen 2 (Trop‐2)
with SN‐38—an active metabolite of irinotecan, which is a topoisomerase I inhibitor. Ap‐
proval was based on findings in the phase I/II multicenter IMMU‐132‐01 trial (ClinicalTri‐
als.gov identifier NCT01631552) [183]. Another drug, enhertu, is an antibody and topoi‐
somerase inhibitor conjugate that targets and attaches to HER2+ cancer cells [142]. Enhertu
is approved for treating adults with unresectable or metastatic HER2‐positive breast can‐
cer [184].
Kadcyla, also known as T‐DM1, is an agent approved by the US FDA to treat patients
with HER2‐positive metastatic breast cancer that have been previously treated with her‐
ceptin and taxane chemotherapy (neoadjuvant treatment). T‐DM1 is an antibody–drug
conjugate targeted therapy in which emtansine is conjugated to Herceptin [141].
The immunotherapy medicine pembrolizumab (brand name: Keytruda) is a human
monoclonal IgG4‐ĸ antibody that is highly selective against the programmed cell death 1
receptor (PD‐1). The addition of pembrolizumab to first‐line chemotherapy significantly
extended progression‐free survival among patients with metastatic TNBC or TNBC that
has resurged and cannot be surgically removed [143]. Recently, USFDA granted

Pharmaceutics 2021, 13, 723

13 of 26

accelerated approval of pembrolizumab in combination with chemotherapy for treating
TNBC patients.
Recently, the combination of atezolizumab plus nab‐paclitaxel has been approved by
FDA as first‐line therapy in patients with PD‐L1+ TNBC [144]. We can, therefore, see that
several diagnostic/ imaging and therapeutic options are currently available for breast can‐
cer management. There has been increasing interest in recent times to combine diagnostic
and therapeutic components within a single system for effective and personalized breast
cancer management. Strategies being investigated in this direction are described in the
next section.
4. Recent Trends in Breast Cancer Theranostics
Traditionally, cancer management is based on identifying tumor lesions through an
appropriate diagnostic imaging modality, followed by treatment with chemotherapy, ra‐
diotherapy, or surgery. However, the disadvantages of these treatments include possibil‐
ity of incomplete surgical resection, off‐target toxicities, low local drug concentrations at
the disease site, and limited drug penetration into tumors due to abnormal vasculature,
which causes elevated interstitial pressure and blood flow stasis [185,186]. Moreover, con‐
ventional methods of assessing drug kinetics involves assessing drug concentration in
plasma, which is not a reliable method to evaluate chemotherapeutic pharmacokinetics
[187,188]. Over the past two decades, personalized medicine has received significant in‐
terest as it can be used to tailor treatment according to patient needs and characteristics,
thus, minimizing side‐effects, resulting in the emergence of theranostics, which is a rela‐
tively new research area [189]. Theranostics is a field of research where a combination of
diagnostic agents and therapeutic agents are used to provide patient‐centered care for the
treatment of cancer and other diseases by providing real‐time monitoring of the drug that
will assist in altering cancer treatment regimens for better therapeutic efficacy [190]. Ac‐
curate diagnosis is crucial for an early therapeutic intervention, failure of which results in
delayed treatment and increased risk of mortality [191].
Theranostic nanotechnology or nanotheranostics is an area where an integrated nan‐
otherapeutic system can be used to simultaneously diagnose, deliver targeted therapy,
and monitor the therapeutic response [192]. A single nanoparticle formulation, conjugated
with targeting ligands, therapeutic agents, and a fluorophore/contrast agent, can be visu‐
alized using different imaging modalities as it crosses biological barriers to target recep‐
tors upregulated by cancer cells and finally releases the drug in the tumor environment in
a controlled manner (Figure 3).
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Figure 3. Schematic diagram representing theranostic approaches in breast cancer management.

Nanotheranostics is being widely explored today as a method of effectively manag‐
ing breast cancer. Nanotheranostic formulations can be tracked using different imaging
modalities following administration so that their targeted accumulation and treatment at
the site of the cancer can be monitored. Lipid‐based carriers, such as liposomes and mi‐
celles, are often used due to their versatility and biocompatibility. Gregoriou et al. recently
developed theranostic micelles using Pluronic F127 block copolymer and Vitamin E‐TPGS
that showed promise as a method of targeted delivery of the phytochemical resveratrol to
treat breast cancer. Coumarin‐6—a fluorophore, can be incorporated to impart imaging
capabilities to the system [193]. Wang et al. targeted EGFR+ TNBCs using a quantum‐dot‐
containing micellar formulation tagged with an anti‐EGFR nanobody. The micelles could
be imaged using the near‐infrared fluorescent quantum dots and could release the anti‐
cancer drug aminoflavone. Significant tumor regression was observed in orthotopic
TNBC mouse models with EGFR+ tumors following administration of the theranostic mi‐
celles by i.v. injection [194]. Parhi et al. functionalized lipid‐based NPs with trastuzumab
to target HER2+ breast cancer cells. The NPs (~72 nm) contained rapamycin (anti‐cancer
drug) and quantum dots (imaging). In vitro studies on SKBR 3 breast cancer cells grown
as a two‐dimensional monolayer and as three‐dimensional spheroids confirmed greater
cellular uptake and therapeutic efficacy than native drug or unmodified NPs [195]. Albu‐
min NPs have also been investigated as a delivery vehicle for theranostic applications. A
human serum albumin‐based NP formulation (~151 nm) encapsulating doxorubicin
(DOX, chemotherapeutic drug) and gadolinium III (MRI contrast agent) was developed
recently and studied against TNBC xenografts grown on the chorioallantoic membrane of
fertilized chick eggs. Persistent NP presence was observed in tumor tissues for at least 15
h, where the NPs significantly reduced the proliferative Ki‐67‐positive fraction of cells in
the xenografts compared to native DOX [196].
Theranostic formulations developed using different polymers have also been suc‐
cessfully investigated in the treatment of breast cancer and its metastases. For example, Li
et al. developed a novel terpolymer using poly(methacrylic acid) and PS 80 covalently
grafted onto starch, which was then used to deliver DOX and multiple imaging agents—
gadolinium (MRI contrast agent) and near‐infrared fluorophore HF750 (fluorescence

Pharmaceutics 2021, 13, 723

15 of 26

imaging), for the treatment of brain metastases of breast cancer. The NPs, when delivered
by tail vein injection, could selectively accumulate and induce apoptosis in cancer cells
while not affecting normal brain cells in a brain metastatic breast cancer SCID mouse
model [197]. Poly lactic‐co‐glycolic acid (PLGA) is a polymer that has been FDA‐approved
for many medical applications and is widely used in nanoparticle‐based drug delivery
strategies. Recently, PLGA NPs were developed and coated with platelet membranes to
form nanoplatelets containing DOX, as well as multiple imaging agents—perfluoropen‐
tane (PFP for ultrasonic imaging), nanocarbon (for photoacoustic imaging and photother‐
mal therapy), and fluorescence imaging. Upon delivery of the NPs to 4T1 breast‐tumor‐
bearing mice and laser irradiation, the light was converted to heat energy by the NPs,
which had a photothermal effect. The heat also led to PFP vaporization for enhanced ul‐
trasonic imaging and release of DOX for therapy [198]. Dong et al. were able to success‐
fully develop a dual‐modal gold‐nanoshelled PLGA magnetic hybrid nanoparticle formu‐
lation that was encapsulated with perfluorooctyl bromide and superparamagnetic iron
oxide nanoparticles and conjugated to anti‐HER2 antibodies (HER2‐GPH NPs). They
were able to monitor the accumulation of these particles using ultrasound and magnetic
resonance while the targeted antibody aided the binding of photothermal agents to the
HER2‐positive breast cancer cells. These particles were able to successfully induce cell
death on exposure to near‐infrared irradiation [199].
Metal‐based NPs have also been explored in breast cancer nanotheranostics. Ruthe‐
nium (Ru) agents also display high anti‐cancer activity with limited cytotoxicity towards
normal cells and are, therefore, an attractive alternative to platinum‐based compounds for
anti‐cancer therapy [200]. Ru‐based compounds can also be employed as imaging agents
by binding to the DNA through non‐covalent interactions [201] and are, thus, useful tools
in theranostic applications. Shen et al. reported the development of a liposome‐based
theranostic formulation containing Ru‐polypyridine complex. The liposome carrier en‐
hanced the cellular internalization of Ru in cancer cells. Intravenous (i.v.) administration
of these nanocarriers in orthotopic murine model of MDA‐MB‐231 human breast cancer
exhibited high accumulation of the particles within the tumor 2 h post injection, along
with a dramatic decrease in the TNBC tumor growth [202]. We have previously developed
theranostic nanoformulations that can co‐deliver a ruthenium compound (therapy) along
with a radionuclide (imaging) to epidermal growth factor (EGFR)‐positive cancer cells
[103]. This formulation is also suitable for the treatment of TNBCs, which tend to overex‐
press EGFR.
In addition to cancer cells, the tumor microenvironment also consists of several other
cell types, including fibroblasts and immune cells, that can play a decisive role in the ef‐
fective distribution of the NPs within the tumor. Strategies that allow for the penetration
of NPs into the tumor microenvironment are, therefore, attractive. Zeng et al. developed
novel HER2‐DOX‐superparamagnetic iron oxide nanoparticles (NP) with a gold shell as
a theranostic approach for the diagnosis and targeted identification of HER2+ BC. The
accumulation of these particles in the tumors of BT474 breast cancer nude mice was high‐
est after 2h of i.v. injection, which was detected by MRI. Additionally, the gold shell‐me‐
diated photothermal effect led to remodeling of the tumor microenvironment by decreas‐
ing cancer‐associated fibroblasts, which resulted in the improved antitumor efficacy of
DOX [203]. NPs usually tend to accumulate in tumor tissues as a result of enhanced per‐
meability and retention effect exerted by long‐circulating nanoparticles. However, the size
of the particles plays a critical role in maintaining these properties. Small nanoparticles
easily penetrate deep into tumor lesions; however, they are pulled back into the blood
stream during circulation, while large particles, on the other hand, are retained easily but
tend to have poor penetration ability [204]. Liu et al. successfully developed a CD44 tar‐
geted tumor‐specific hyaluronidase‐degradable hyaluronic acid, cationic bovine serum
albumin‐protected gold nanocluster that was loaded with indocyanine green for tumor
fluorescence imaging and a chemotherapeutic drug paclitaxel. On subcutaneous injection
of the NPs in tumor‐bearing Balb/c mice, these particles displayed size‐reducible
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properties as a result of the presence of hyaluronidase leading to highly homogenous in‐
tra‐tumor distribution of the NPs [205,206].
Nanotheranostic formulations can also be used to provide hyperthermia in cells to
promote cell membrane permeabilization causing the destruction of the tumorous mass.
Burke et al. used near infrared stimulation of multiwalled carbon nanotubes for photo‐
thermal therapy, which led to increased permeability of cell membranes and rapid cell
death. This system has the potential to be used for theranostic applications if combined
with an anti‐cancer agent [207]. Another promising strategy in theranostics is using an
injectable thermoresponsive hydrogel for local therapy of breast cancer. Wu et al. demon‐
strated that injecting a supramolecular thermoresponsive hydrogel such as poly(N‐acry‐
loyl glycinamide‐co‐acrylamide) hydrogel along with polydopamine (PDA) coated‐gold
nanoparticles (AuNPs) and loading the carrier with DOX exhibited an excellent photo‐
thermal effect, along with sustained release of the anticancer drug [208].
It is clear from the above research that breast cancer nanotheranostics is a rapidly
growing area that holds great promise as a method of combining cutting‐edge technologies
within a single platform to deliver breast cancer therapies in a targeted, sustained, and effec‐
tive manner. We can integrate contrast agents for different imaging modalities and an
anti‐cancer therapeutic agent into a single formulation for targeted theranostic drug de‐
livery, which can minimize patient discomfort while providing personalized medicine.
5. Conclusions and Future Outlook
In this review, we have highlighted some of the common methods of breast cancer
diagnosis and treatment and the role of the emerging area of breast cancer theranostics in
integrating diagnostics and therapy within a single platform to provide patient‐specific
therapy. Early detection and treatment of breast cancer is crucial in the reduction of breast
cancer mortality rate. The methods of diagnosis and treatment of breast cancer has under‐
gone tremendous changes over the past two decades, and the focus is on managing and
treating the disease with minimal patient discomfort, increased patient compliance, and
reduced off‐target side effects. Nanomedicine allows for the targeted delivery and con‐
trolled release of the encapsulated drugs at the tumor site, thus, altering the bioavailability
and drug pharmacokinetics while simultaneously enhancing permeability and retention
in the tumor and minimizing severe side‐effects to the healthy cells. Theranostics has
emerged as an invaluable tool in personalized medicine as these multifunctional plat‐
forms can be used for the simultaneous detection, treatment, and management of cancers.
Despite the undeniable potential of nanotheranostic formulations, there are several factors
to be taken into consideration while developing and testing these platforms and before
taking them into the market. A major challenge is in the manufacturing, scale‐up, and
reproducibility owing to the complexity of incorporating multiple functionalities into a
single platform while maintaining its dimensions in the nanoscale range. Extensive re‐
search needs to be conducted to determine the optimal dose that can simultaneously pro‐
duce a strong signal for imaging while maintaining the desired drug release kinetics for
therapy. The platform must also have minimal or negligible toxic interactions with the
surrounding biological tissues. Depth of penetration is a significant challenge when using
imaging modalities with theranostic formulations; therefore, imaging agents that can be
used to obtain high resolution images independent of tissue depth are preferred. The ma‐
terials used to develop the theranostic system must be optimized to prevent release of the
incorporated imaging agent and premature release of the encapsulated therapeutics.
While stimuli‐responsive “smart” materials may be used for on‐demand release of thera‐
peutics in response to changes in the surrounding environment (e.g., temperature, pH,
magnetic field), this introduces more complexity to the system and can possibly impede
its clinical translation. Different type of breast tumors can upregulate different receptors
on their surfaces, and the theranostic system will need to be optimized against each type
of breast cancer in order to provide personalized therapy. Nevertheless, it is evident that
theranostic nanomedicine holds tremendous potential for breast cancer diagnosis and
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targeted, personalized treatment. Since theranostics is an emerging research area, we can
expect to see new multifunctional formulations enter clinical trials in the near future that
can be tracked following administration and provide targeted and effective breast cancer
therapy.
Author Contributions: Conceptualization, A.B.; writing—original draft preparation, A.B. and A.G.;
writing—reviewing & editing, A.B., A.G. and J.U.M.; funding acquisition, J.U.M. All authors have
read and agreed to the published version of the manuscript.
Funding: This work received funding support from the Rhode Island Institutional Development
Award (IDeA) Network of Biomedical Research Excellence from the National Institute of General
Medical Sciences of the National Institutes of Health under grant number P20GM103430.
Institutional Review Board Statement: Not applicable.
Informed Consent Statement: Not applicable.
Data Availability Statement: Not applicable.
Conflicts of Interest: The authors declare no conflict of interest.

References
1.
2.
3.
4.
5.
6.

7.
8.
9.
10.

11.
12.
13.
14.
15.
16.
17.
18.

Ebeid, N.I. Egyptian Medicine in the Days of the Pharaohs; General—Egyptian Book Organization: Cairo, Egypt, 1999; ISBN
9789770164228.
Siegel, R.L.; Miller, K.D.; Fuchs, H.E.; Jemal, A. Cancer Statistics, 2021. CA: A Cancer J. Clin. 2021, 71, 7–33, doi:10.3322/caac.21654.
Duncan, W.; Kerr, G.R. The curability of breast cancer. Br. Med. J. 1976, 2, 781–783.
Juanpere, S.; Perez, E.; Huc, O.; Motos, N.; Pont, J.; Pedraza, S. Imaging of breast implants‐a pictorial review. Insights Into Imaging
2011, 2, 653–670, doi:10.1007/s13244‐011‐0122‐3.
Basilion, J. Breast imaging technology: Current and future technologies for breast cancer imaging. Breast Cancer Res. 2001, 3, 13–
14, doi:10.1186/bcr264.
Iranmakani, S.; Mortezazadeh, T.; Sajadian, F.; Ghaziani, M.F.; Ghafari, A.; Khezerloo, D.; Musa, A.E. A review of various
modalities in breast imaging: technical aspects and clinical outcomes. Egypt. J. Radiol. Nucl. Med. 2020, 51, 57, doi:10.1186/s43055‐
020‐00175‐5.
Zhang, X.‐H.; Xiao, C. Diagnostic Value of Nineteen Different Imaging Methods for Patients with Breast Cancer: a Network
Meta‐Analysis. Cell. Physiol. Biochem. 2018, 46, 2041–2055, doi:10.1159/000489443.
Sant, M.; Allemani, C.; Berrino, F.; Coleman, M.P.; Aareleid, T.; Chaplain, G.; Coebergh, J.W.; Colonna, M.; Crosignani, P.;
Danzon, A.; et al. Breast carcinoma survival in Europe and the United States. Cancer 2004, 100, 715–722, doi:10.1002/cncr.20038.
Zeeshan, M.; Salam, B.; Khalid, Q.S.B.; Alam, S.; Sayani, R. Diagnostic Accuracy of Digital Mammography in the Detection of
Breast Cancer. Cureus 2018, 10, e2448–e2448, doi:10.7759/cureus.2448.
von Euler‐Chelpin, M.; Lillholm, M.; Vejborg, I.; Nielsen, M.; Lynge, E. Sensitivity of screening mammography by density and
texture: a cohort study from a population‐based screening program in Denmark. Breast Cancer Res. 2019, 21, 111,
doi:10.1186/s13058‐019‐1203‐3.
Devi, R.R.; Anandhamala, G. Recent Trends in Medical Imaging Modalities and Challenges for Diagnosing Breast Cancer.
Biomed. Pharmacol. J. 2018, 11, 1649–1658.
Procz, S.; Roque, G.; Avila, C.; Racedo, J.; Rueda, R.; Santos, I.; Fiederle, M. Investigation of CdTe, GaAs, Se and Si as Sensor
Materials for Mammography. IEEE Trans. Med. Imaging 2020, 39, 3766–3778, doi:10.1109/TMI.2020.3004648.
Mann, R.M.; Kuhl, C.K.; Moy, L. Contrast‐enhanced MRI for breast cancer screening. J. Magn. Reson. Imaging 2019, 50, 377–390,
doi:10.1002/jmri.26654.
Wallyn, J.; Anton, N.; Akram, S.; Vandamme, T.F. Biomedical Imaging: Principles, Technologies, Clinical Aspects, Contrast
Agents, Limitations and Future Trends in Nanomedicines. Pharm. Res. 2019, 36, 78, doi:10.1007/s11095‐019‐2608‐5.
Grover, V.P.B.; Tognarelli, J.M.; Crossey, M.M.E.; Cox, I.J.; Taylor‐Robinson, S.D.; McPhail, M.J.W. Magnetic Resonance Imaging:
Principles and Techniques: Lessons for Clinicians. J. Clin. Exp. Hepatol. 2015, 5, 246–255, doi:10.1016/j.jceh.2015.08.001.
Fardanesh, R.; Marino, M.A.; Avendano, D.; Leithner, D.; Pinker, K.; Thakur, S.B. Proton MR spectroscopy in the breast:
Technical innovations and clinical applications. J. Magn. Reson. Imaging 2019, 50, 1033–1046, doi:10.1002/jmri.26700.
Hu, J.; Feng, W.; Hua, J.; Jiang, Q.; Xuan, Y.; Li, T.; Haacke, E.M. A high spatial resolution in vivo 1H magnetic resonance
spectroscopic imaging technique for the human breast at 3 T. Med. Phys. 2009, 36, 4870–4877, doi:10.1118/1.3213087.
Alam, M.S.; Sajjad, Z.; Hafeez, S.; Akhter, W. Magnetic resonance spectroscopy in focal brain lesions. J. Pak. Med. Assoc. 2011,

Pharmaceutics 2021, 13, 723

19.

20.
21.
22.

23.
24.
25.
26.

27.
28.

29.
30.
31.
32.
33.

34.
35.

36.
37.

38.
39.

18 of 26

61, 540–543.
Cai, H.; Liu, L.; Peng, Y.; Wu, Y.; Li, L. Diagnostic assessment by dynamic contrast‐enhanced and diffusion‐weighted magnetic
resonance in differentiation of breast lesions under different imaging protocols. BMC Cancer 2014, 14, 366, doi:10.1186/1471‐
2407‐14‐366.
Jansen, S.A.; Fan, X.; Karczmar, G.S.; Abe, H.; Schmidt, R.A.; Giger, M.; Newstead, G.M. DCEMRI of breast lesions: is kinetic
analysis equally effective for both mass and nonmass‐like enhancement? Med. Phys. 2008, 35, 3102–3109, doi:10.1118/1.2936220.
Tao, W.; Hu, C.; Bai, G.; Zhu, Y.; Zhu, Y. Correlation between the dynamic contrast‐enhanced MRI features and prognostic
factors in breast cancer: A retrospective case‐control study. Medicine 2018, 97, doi:10.1097/MD.0000000000011530.
Pereira, N.P.; Curi, C.; Osório, C.A.B.T.; Marques, E.F.; Makdissi, F.B.; Pinker, K.; Bitencourt, A.G. V Diffusion‐Weighted
Magnetic Resonance Imaging of Patients with Breast Cancer Following Neoadjuvant Chemotherapy Provides Early Prediction
of Pathological Response – A Prospective Study. Sci. Rep. 2019, 9, 16372, doi:10.1038/s41598‐019‐52785‐3.
Narayanan, D.; Berg, W.A. Dedicated Breast Gamma Camera Imaging and Breast PET: Current Status and Future Directions.
PET Clin. 2018, 13, 363–381, doi:10.1016/j.cpet.2018.02.008.
Ferrucci, M.; Franceschini, G.; Douek, M. New techniques for sentinel node biopsy in breast cancer. Trans. Cancer Res. 2018,
doi:10.21037/tcr.2018.02.07.
Nandu, V. V; Chaudhari, M.S. Efficacy of Sentinel Lymph Node Biopsy in Detecting Axillary Metastasis in Breast Cancer
Using Methylene Blue. Indian J. Surg. Oncol. 2017, 8, 109–112, doi:10.1007/s13193‐016‐0616‐z.
Brem, R.F.; Ruda, R.C.; Yang, J.L.; Coffey, C.M.; Rapelyea, J.A. Breast‐Specific γ‐Imaging for the Detection of
Mammographically Occult Breast Cancer in Women at Increased Risk. J. Nucl. Med. 2016, 57, 678–684,
doi:10.2967/jnumed.115.168385.
Holbrook, A.; Newel, M.S. Alternative Screening for Women With Dense Breasts: Breast‐Specific Gamma Imaging (Molecular
Breast Imaging). Am. J. Roentgenol. 2015, 204, 252–256, doi:10.2214/AJR.14.13525.
Liu, H.; Zhan, H.; Sun, D.; Zhang, Y. Comparison of BSGI, MRI, mammography, and ultrasound for the diagnosis of breast
lesions and their correlations with specific molecular subtypes in Chinese women. BMC Med. Imaging 2020, 20, 98,
doi:10.1186/s12880‐020‐00497‐w.
Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann. Intern. Med. 2016, 164, 279–
296, doi:10.7326/M15‐2886.
Gøtzsche, P.C.; Jørgensen, K.J. Screening for breast cancer with mammography. Cochrane Database Syst. Rev. 2013, 2013,
CD001877, doi:10.1002/14651858.CD001877.pub5.
Bhan, A. Comparative Analysis of Pre‐Processing Techniques for Mammogram Image Enhancement. In Proceedings of the
INCON VIII 2013: International Conference on Ongoing Research in Management and IT, Pune, India, 11–13 January 2013.
Sundaram, D.K.M.; D.Sasikala; Rani, P. A Study On Preprocessing A MammogramImage Using Adaptive Median Filter. Int. J.
Innov. Res. Sci. Eng. Technol. 2014, 3, 10333–10337.
Mandelblatt, J.S.; Cronin, K.A.; Bailey, S.; Berry, D.A.; de Koning, H.J.; Draisma, G.; Huang, H.; Lee, S.J.; Munsell, M.; Plevritis,
S.K.; et al. Effects of mammography screening under different screening schedules: Model estimates of potential benefits and
harms. Ann. Intern. Med. 2009, 151, 738–747, doi:10.7326/0003‐4819‐151‐10‐200911170‐00010.
Nelson, H.D.; Tyne, K.; Naik, A.; Bougatsos, C.; Chan, B.K.; Humphrey, L. Screening for breast cancer: an update for the U.S.
Preventive Services Task Force. Ann. Intern. Med. 2009, 151, 727–37, W237‐42, doi:10.7326/0003‐4819‐151‐10‐200911170‐00009.
Sprague, B.L.; Conant, E.F.; Onega, T.; Garcia, M.P.; Beaber, E.F.; Herschorn, S.D.; Lehman, C.D.; Tosteson, A.N.A.; Lacson, R.;
Schnall, M.D.; et al. Variation in Mammographic Breast Density Assessments Among Radiologists in Clinical Practice: A
Multicenter Observational Study. Ann. Intern. Med. 2016, 165, 457–464, doi:10.7326/M15‐2934.
Yala, A.; Lehman, C.; Schuster, T.; Portnoi, T.; Barzilay, R. A Deep Learning Mammography‐based Model for Improved Breast
Cancer Risk Prediction. Radiology 2019, 292, 60–66, doi:10.1148/radiol.2019182716.
Torrisi, L.; Restuccia, N.; Torrisi, A. Study of gold nanoparticles for mammography diagnostic and radiotherapy
improvements. Rep. Pract. Oncol. Radiother. J. Greatpoland Cancer Cent. Pozn. Pol. Soc. Radiat. Oncol. 2019, 24, 450–457,
doi:10.1016/j.rpor.2019.07.005.
Graves, M.J.; Zhu, C. Basic Principles of Magnetic Resonance Imaging. In 3D Imaging Technologies in Atherosclerosis; Trivedi, R.,
Saba, L., Suri, J.S., Eds.; Springer: Boston, MA, USA, 2015; pp. 153–169. ISBN 978‐1‐4899‐7618‐5.
Jethava, A.; Ali, S.; Wakefield, D.; Crowell, R.; Sporn, J.; Vrendenburgh, J. Diagnostic Accuracy of MRI in Predicting Breast
Tumor Size: Comparative Analysis of MRI vs Histopathological Assessed Breast Tumor Size. Conn. Med. 2015, 79, 261–267.

Pharmaceutics 2021, 13, 723

40.

41.
42.

43.

44.

45.
46.
47.

48.
49.

50.
51.
52.

53.
54.
55.
56.
57.
58.
59.
60.
61.

19 of 26

Grimsby, G.M.; Gray, R.; Dueck, A.; Carpenter, S.; Stucky, C.‐C.; Aspey, H.; Giurescu, M.E.; Pockaj, B. Is there concordance of
invasive breast cancer pathologic tumor size with magnetic resonance imaging? Am. J. Surg. 2009, 198, 500–504,
doi:10.1016/j.amjsurg.2009.07.012.
Goldsmith, M.; Koutcher, J.A.; Damadian, R. NMR in cancer, XIII: application of the NMR malignancy index to human
mammary tumours. Br. J. Cancer 1978, 38, 547–554, doi:10.1038/bjc.1978.243.
Niell, B.L.; Gavenonis, S.C.; Motazedi, T.; Chubiz, J.C.; Halpern, E.P.; Rafferty, E.A.; Lee, J.M. Auditing a Breast MRI Practice:
Performance Measures for Screening and Diagnostic Breast MRI. J. Am. Coll. Radiol. 2014, 11, 883–889,
doi:10.1016/j.jacr.2014.02.003.
Michel, S.C.A.; Keller, T.M.; Fröhlich, J.M.; Fink, D.; Caduff, R.; Seifert, B.; Marincek, B.; Kubik‐Huch, R.A. Preoperative Breast
Cancer Staging: MR Imaging of the Axilla with Ultrasmall Superparamagnetic Iron Oxide Enhancement. Radiology 2002, 225,
527–536, doi:10.1148/radiol.2252011605.
Ayat, N.R.; Vaidya, A.; Yeung, G.A.; Buford, M.N.; Hall, R.C.; Qiao, P.L.; Yu, X.; Lu, Z.‐R. Effective MR Molecular Imaging of
Triple Negative Breast Cancer With an EDB‐Fibronectin‐Specific Contrast Agent at Reduced Doses. Front. Oncol. 2019, 9, 1351,
doi:10.3389/fonc.2019.01351.
Leithner, D.; Moy, L.; Morris, E.A.; Marino, M.A.; Helbich, T.H.; Pinker, K. Abbreviated MRI of the Breast: Does It Provide
Value? J. Magn. Reson. Imaging 2019, 49, e85–e100, doi:10.1002/jmri.26291.
Peters, N.H.G.M.; Borel Rinkes, I.H.M.; Zuithoff, N.P.A.; Mali, W.P.T.M.; Moons, K.G.M.; Peeters, P.H.M. Meta‐analysis of MR
imaging in the diagnosis of breast lesions. Radiology 2008, 246, 116–124, doi:10.1148/radiol.2461061298.
Sardanelli, F.; Podo, F.; D’Agnolo, G.; Verdecchia, A.; Santaquilani, M.; Musumeci, R.; Trecate, G.; Manoukian, S.; Morassut, S.;
de Giacomi, C.; et al. Multicenter comparative multimodality surveillance of women at genetic‐familial high risk for breast
cancer (HIBCRIT study): interim results. Radiology 2007, 242, 698–715, doi:10.1148/radiol.2423051965.
Rahbar, H.; Partridge, S.C. Multiparametric MR Imaging of Breast Cancer. Magn. Reson. Imaging Clin. North Am. 2016, 24, 223–
238, doi:10.1016/j.mric.2015.08.012.
Teifke, A.; Behr, O.; Schmidt, M.; Victor, A.; Vomweg, T.W.; Thelen, M.; Lehr, H.‐A. Dynamic MR imaging of breast lesions:
correlation with microvessel distribution pattern and histologic characteristics of prognosis. Radiology 2006, 239, 351–360,
doi:10.1148/radiol.2392050205.
Lee, S.H.; Cho, N.; Kim, S.J.; Cha, J.H.; Cho, K.S.; Ko, E.S.; Moon, W.K. Correlation between high resolution dynamic MR features
and prognostic factors in breast cancer. Korean J. Radiol. 2008, 9, 10–18, doi:10.3348/kjr.2008.9.1.10.
Choi, E.J.; Choi, H.; Choi, S.A.; Youk, J.H. Dynamic contrast‐enhanced breast magnetic resonance imaging for the prediction of
early and late recurrences in breast cancer. Medicine 2016, 95, e5330–e5330, doi:10.1097/MD.0000000000005330.
Wang, H.; Hu, Y.; Li, H.; Xie, Y.; Wang, X.; Wan, W. Preliminary study on identification of estrogen receptor‐positive breast
cancer subtypes based on dynamic contrast‐enhanced magnetic resonance imaging (DCE‐MRI) texture analysis. Gland Surg.
2020, 9, 622–628, doi:10.21037/gs.2020.04.01.
Gillman, J.; Toth, H.K.; Moy, L. The Role of Dynamic Contrast‐Enhanced Screening Breast MRI in Populations at Increased Risk
for Breast Cancer. Women’s Health 2014, 10, 609–622, doi:10.2217/WHE.14.61.
Turnbull, L.W. Dynamic contrast‐enhanced MRI in the diagnosis and management of breast cancer. NMR Biomed. 2009, 22, 28–
39, doi:10.1002/nbm.1273.
Amornsiripanitch, N.; Bickelhaupt, S.; Shin, H.J.; Dang, M.; Rahbar, H.; Pinker, K.; Partridge, S.C. Diffusion‐weighted MRI for
Unenhanced Breast Cancer Screening. Radiology 2019, 293, 504–520, doi:10.1148/radiol.2019182789.
Glaser, K.J.; Manduca, A.; Ehman, R.L. Review of MR elastography applications and recent developments. J. Magn. Reson.
Imaging 2012, 36, 757–774, doi:10.1002/jmri.23597.
Patel, B.K.; Samreen, N.; Zhou, Y.; Chen, J.; Brandt, K.; Ehman, R.; Pepin, K. MR Elastography of the Breast: Evolution of
Technique, Case Examples, and Future Directions. Clin. Breast Cancer 2021, 21, e102–e111, doi:10.1016/j.clbc.2020.08.005.
Hawley, J.R.; Kalra, P.; Mo, X.; Raterman, B.; Yee, L.D.; Kolipaka, A. Quantification of breast stiffness using MR elastography at
3 Tesla with a soft sternal driver: A reproducibility study. J. Magn. Reson. Imaging 2017, 45, 1379–1384, doi:10.1002/jmri.25511.
McKnight, A.L.; Kugel, J.L.; Rossman, P.J.; Manduca, A.; Hartmann, L.C.; Ehman, R.L. MR Elastography of Breast Cancer:
Preliminary Results. Am. J. Roentgenol. 2002, 178, 1411–1417, doi:10.2214/ajr.178.6.1781411.
Pepin, K.M.; Ehman, R.L.; McGee, K.P. Magnetic resonance elastography (MRE) in cancer: Technique, analysis, and applications.
Prog. Nucl. Magn. Reson. Spectrosc. 2015, 90–91, 32–48, doi:10.1016/j.pnmrs.2015.06.001.
Sinkus, R.; Siegmann, K.; Xydeas, T.; Tanter, M.; Claussen, C.; Fink, M. MR elastography of breast lesions: understanding the
solid/liquid duality can improve the specificity of contrast‐enhanced MR mammography. Magn. Reson. Med. 2007, 58, 1135–
1144, doi:10.1002/mrm.21404.

Pharmaceutics 2021, 13, 723

62.

63.
64.

65.
66.

67.
68.
69.

70.
71.

72.

73.
74.
75.

76.
77.

78.

79.

80.
81.
82.

20 of 26

Manduca, A.; Oliphant, T.E.; Dresner, M.A.; Mahowald, J.L.; Kruse, S.A.; Amromin, E.; Felmlee, J.P.; Greenleaf, J.F.; Ehman, R.L.
Magnetic resonance elastography: non‐invasive mapping of tissue elasticity. Med. Image Anal. 2001, 5, 237–254,
doi:10.1016/s1361‐8415(00)00039‐6.
Lorenzen, J.; Sinkus, R.; Lorenzen, M.; Dargatz, M.; Leussler, C.; Röschmann, P.; Adam, G. MR elastography of the
breast:preliminary clinical results. Rofo: Fortschr. Geb. Rontgenstrahlen Nukl. 2002, 174, 830–834, doi:10.1055/s‐2002‐32690.
Malayeri, A.A.; El Khouli, R.H.; Zaheer, A.; Jacobs, M.A.; Corona‐Villalobos, C.P.; Kamel, I.R.; Macura, K.J. Principles and
Applications of Diffusion‐weighted Imaging in Cancer Detection, Staging, and Treatment Follow‐up. RadioGraphics 2011, 31,
1773–1791, doi:10.1148/rg.316115515.
Petralia, G.; Bonello, L.; Priolo, F.; Summers, P.; Bellomi, M. Breast MR with special focus on DW‐MRI and DCE‐MRI. Cancer
Imaging: Off. Publ. Int. Cancer Imaging Soc. 2011, 11, 76–90, doi:10.1102/1470‐7330.2011.0014.
Baron, P.; Dorrius, M.D.; Kappert, P.; Oudkerk, M.; Sijens, P.E. Diffusion‐weighted imaging of normal fibroglandular breast
tissue: influence of microperfusion and fat suppression technique on the apparent diffusion coefficient. NMR Biomed. 2010, 23,
399–405, doi:10.1002/nbm.1475.
Durur‐Subasi, I. DW‐MRI of the breast: A pictorial review. Insights Into Imaging 2019, 10, 61, doi:10.1186/s13244‐019‐0745‐3.
Baltzer, P.A.T.; Kapetas, P.; Sodano, C.; Dietzel, M.; Pinker, K.; Helbich, T.H.; Clauser, P. Contrast agent‐free breast MRI :
Advantages and potential disadvantages. Der Radiol. 2019, 59, 510–516, doi:10.1007/s00117‐019‐0524‐7.
Baltzer, P.; Mann, R.M.; Iima, M.; Sigmund, E.E.; Clauser, P.; Gilbert, F.J.; Martincich, L.; Partridge, S.C.; Patterson, A.; Pinker,
K.; et al. Diffusion‐weighted imaging of the breast‐a consensus and mission statement from the EUSOBI International Breast
Diffusion‐Weighted Imaging working group. Eur. Radiol. 2020, 30, 1436–1450, doi:10.1007/s00330‐019‐06510‐3.
Bolan, P.J.; Meisamy, S.; Baker, E.H.; Lin, J.; Emory, T.; Nelson, M.; Everson, L.I.; Yee, D.; Garwood, M. In vivo quantification of
choline compounds in the breast with 1H MR spectroscopy. Magn. Reson. Med. 2003, 50, 1134–1143, doi:10.1002/mrm.10654.
Jagannathan, N.R.; Kumar, M.; Seenu, V.; Coshic, O.; Dwivedi, S.N.; Julka, P.K.; Srivastava, A.; Rath, G.K. Evaluation of total
choline from in‐vivo volume localized proton MR spectroscopy and its response to neoadjuvant chemotherapy in locally
advanced breast cancer. Br. J. Cancer 2001, 84, 1016–1022, doi:10.1054/bjoc.2000.1711.
Meisamy, S.; Bolan, P.J.; Baker, E.H.; Pollema, M.G.; Le, C.T.; Kelcz, F.; Lechner, M.C.; Luikens, B.A.; Carlson, R.A.; Brandt, K.R.;
et al. Adding in Vivo Quantitative 1H MR Spectroscopy to Improve Diagnostic Accuracy of Breast MR Imaging: Preliminary
Results of Observer Performance Study at 4.0 T. Radiology 2005, 236, 465–475, doi:10.1148/radiol.2362040836.
Stanwell, P.; Mountford, C. In Vivo Proton MR Spectroscopy of the Breast. RadioGraphics 2007, 27, S253–S266,
doi:10.1148/rg.27si075519.
Liberti, M. V; Locasale, J.W. The Warburg Effect: How Does it Benefit Cancer Cells? Trends Biochem. Sci. 2016, 41, 211–218,
doi:10.1016/j.tibs.2015.12.001.
Flavell, R.R.; Naeger, D.M.; Mari Aparici, C.; Hawkins, R.A.; Pampaloni, M.H.; Behr, S.C. Malignancies with Low
Fluorodeoxyglucose Uptake at PET/CT: Pitfalls and Prognostic Importance: Resident and Fellow Education Feature.
RadioGraphics 2016, 36, 293–294, doi:10.1148/rg.2016150073.
Kawada, K.; Iwamoto, M.; Sakai, Y. Mechanisms underlying (18)F‐fluorodeoxyglucose accumulation in colorectal cancer. World
J. Radiol. 2016, 8, 880–886, doi:10.4329/wjr.v8.i11.880.
Kadoya, T.; Aogi, K.; Kiyoto, S.; Masumoto, N.; Sugawara, Y.; Okada, M. Role of maximum standardized uptake value in
fluorodeoxyglucose positron emission tomography/computed tomography predicts malignancy grade and prognosis of
operable breast cancer: a multi‐institute study. Breast Cancer Res. Treat. 2013, 141, 269–275, doi:10.1007/s10549‐013‐2687‐7.
Jin, S.; Kim, S.‐B.; Ahn, J.‐H.; Jung, K.H.; Ahn, S.H.; Son, B.H.; Lee, J.W.; Gong, G.; Kim, H.O.; Moon, D.H. 18 F‐
fluorodeoxyglucose uptake predicts pathological complete response after neoadjuvant chemotherapy for breast cancer: a
retrospective cohort study. J. Surg. Oncol. 2013, 107, 180–187, doi:10.1002/jso.23255.
Narayanan, D.; Madsen, K.S.; Kalinyak, J.E.; Berg, W.A. Interpretation of Positron Emission Mammography and MRI by
Experienced Breast Imaging Radiologists: Performance and Observer Reproducibility. Am. J. Roentgenol. 2011, 196, 971–981,
doi:10.2214/AJR.10.5081.
Hsu, D.F.C.; Freese, D.L.; Levin, C.S. Breast‐Dedicated Radionuclide Imaging Systems. J. Nucl. Med. 2016, 57, 40S‐45S,
doi:10.2967/jnumed.115.157883.
Giammarile, F.; Castellucci, P.; Dierckx, R.; Estrada Lobato, E.; Farsad, M.; Hustinx, R.; Jalilian, A.; Pellet, O.; Rossi, S.; Paez, D.
Non‐FDG PET/CT in Diagnostic Oncology: a pictorial review. Eur. J. Hybrid Imaging 2019, 3, 20, doi:10.1186/s41824‐019‐0066‐2.
Blanchet, E.M.; Millo, C.; Martucci, V.; Maass‐Moreno, R.; Bluemke, D.A.; Pacak, K. Integrated whole‐body PET/MRI with 18F‐
FDG, 18F‐FDOPA, and 18F‐FDA in paragangliomas in comparison with PET/CT: NIH first clinical experience with a single‐
injection, dual‐modality imaging protocol. Clin. Nucl. Med. 2014, 39, 243–250, doi:10.1097/RLU.0000000000000289.

Pharmaceutics 2021, 13, 723

83.
84.
85.

86.

87.

88.
89.

90.
91.
92.
93.

94.

95.
96.
97.
98.

99.
100.
101.

102.
103.

21 of 26

Wibmer, A.G.; Hricak, H.; Ulaner, G.A.; Weber, W. Trends in oncologic hybrid imaging. Eur. J. Hybrid Imaging 2018, 2, 1,
doi:10.1186/s41824‐017‐0019‐6.
Escalona, S.; Blasco, J.A.; Reza, M.M.; Andradas, E.; Gómez, N. A systematic review of FDG‐PET in breast cancer. Med. Oncol.
(Northwoodlondonengland) 2010, 27, 114–129, doi:10.1007/s12032‐009‐9182‐3.
Jørgensen, J.T.; Norregaard, K.; Simón Martín, M.; Oddershede, L.B.; Kjaer, A. Non‐invasive Early Response Monitoring of
Nanoparticle‐assisted Photothermal Cancer
Therapy Using (18)F‐FDG, (18)F‐FLT, and (18)F‐FET PET/CT Imaging.
Nanotheranostics 2018, 2, 201–210, doi:10.7150/ntno.24478.
Lyman, G.H.; Somerfield, M.R.; Bosserman, L.D.; Perkins, C.L.; Weaver, D.L.; Giuliano, A.E. Sentinel Lymph Node Biopsy for
Patients With Early‐Stage Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J. Clin.
Oncol. 2016, 35, 561–564, doi:10.1200/JCO.2016.71.0947.
Cox, C.E.; Kiluk, J. V; Riker, A.I.; Cox, J.M.; Allred, N.; Ramos, D.C.; Dupont, E.L.; Vrcel, V.; Diaz, N.; Boulware, D. Significance
of sentinel lymph node micrometastases in human breast cancer. J. Am. Coll. Surg. 2008, 206, 261–268,
doi:10.1016/j.jamcollsurg.2007.08.024.
Chen, S.L.; Iddings, D.M.; Scheri, R.P.; Bilchik, A.J. Lymphatic mapping and sentinel node analysis: current concepts and
applications. CA: A Cancer J. Clin. 2006, 56, 292–297, doi:10.3322/canjclin.56.5.292.
Kang, J.; Chang, J.H.; Kim, S.M.; Lee, H.J.; Kim, H.; Wilson, B.C.; Song, T.‐K. Real‐time sentinel lymph node biopsy guidance
using combined ultrasound, photoacoustic, fluorescence imaging: in vivo proof‐of‐principle and validation with nodal
obstruction. Sci. Rep. 2017, 7, 45008, doi:10.1038/srep45008.
Shaikh, K.; Krishnan, S.; Thanki, R. Breast Cancer Detection and Diagnosis Using AI. In Artificial Intelligence in Breast Cancer
Early Detection and Diagnosis; Springer International Publishing: Cham, Switzerland, 2021; pp. 79–92. ISBN 978‐3‐030‐59208‐0.
Liu, H.; Zhan, H.; Sun, D. Comparison of 99mTc‐MIBI scintigraphy, ultrasound, and mammography for the diagnosis of BI‐
RADS 4 category lesions. BMC Cancer 2020, doi:10.1186/s12885‐020‐06938‐7.
Gong, Z.; Williams, M.B. Comparison of breast specific gamma imaging and molecular breast tomosynthesis in breast cancer
detection: Evaluation in phantoms. Med. Phys. 2015, 42, 4250–4259, doi:10.1118/1.4922398.
Rechtman, L.R.; Lenihan, M.J.; Lieberman, J.H.; Teal, C.B.; Torrente, J.; Rapelyea, J.A.; Brem, R.F. Breast‐Specific Gamma
Imaging for the Detection of Breast Cancer in Dense Versus Nondense Breasts. Am. J. Roentgenol. 2014, 202, 293–298,
doi:10.2214/AJR.13.11585.
Zhang, Z.; Wang, W.; Wang, X.; Yu, X.; Zhu, Y.; Zhan, H.; Chen, Z.; Li, B.; Huang, J. Breast‐specific gamma imaging or
ultrasonography as adjunct imaging diagnostics in women with mammographically dense breasts. Eur. Radiol. 2020, 30, 6062–
6071, doi:10.1007/s00330‐020‐06950‐2.
Surti, S. Radionuclide methods and instrumentation for breast cancer detection and diagnosis. Semin. Nucl. Med. 2013, 43, 271–
280, doi:10.1053/j.semnuclmed.2013.03.003.
Urbano, N.; Scimeca, M.; Tancredi, V.; Bonanno, E.; Schillaci, O. 99mTC‐sestamibi breast imaging: Current status, new ideas
and future perspectives. Semin. Cancer Biol. 2020, doi:10.1016/j.semcancer.2020.01.007.
Candelaria, R.; Fornage, B.D. Second‐look US examination of MR‐detected breast lesions. J. Clin. Ultrasound 2011, 39, 115–121,
doi:10.1002/jcu.20784.
Sridharan, A.; Eisenbrey, J.R.; Machado, P.; Ojeda‐Fournier, H.; Wilkes, A.; Sevrukov, A.; Mattrey, R.F.; Wallace, K.; Chalek,
C.L.; Thomenius, K.E.; et al. Quantitative analysis of vascular heterogeneity in breast lesions using contrast‐enhanced 3‐D
harmonic and subharmonic ultrasound imaging. IEEE Trans. Ultrason. Ferroelectr. Freq. Control 2015, 62, 502–510,
doi:10.1109/tuffc.2014.006886.
Kaplan, S.S. Automated whole breast ultrasound. Radiol. Clin. North Am. 2014, 52, 539–546, doi:10.1016/j.rcl.2014.01.002.
Skerl, K.; Vinnicombe, S.; Thomson, K.; McLean, D.; Giannotti, E.; Evans, A. Anisotropy of Solid Breast Lesions in 2D Shear
Wave Elastography is an Indicator of Malignancy. Acad. Radiol. 2016, 23, 53–61, doi:10.1016/j.acra.2015.09.016.
Bamber, J.; Cosgrove, D.; Dietrich, C.F.; Fromageau, J.; Bojunga, J.; Calliada, F.; Cantisani, V.; Correas, J.‐M.; D’Onofrio, M.;
Drakonaki, E.E.; et al. EFSUMB guidelines and recommendations on the clinical use of ultrasound elastography. Part 1: Basic
principles and technology. Ultraschall in der Medizin (Stuttgart, Germany: 1980) 2013, 34, 169–184, doi:10.1055/s‐0033‐1335205.
Wan, C.F.; Du, J.; Fang, H.; Li, F.H.; Zhu, J.S.; Liu, Q. Enhancement patterns and parameters of breast cancers at contrast‐
enhanced US: correlation with prognostic factors. Radiology 2012, 262, 450–459, doi:10.1148/radiol.11110789.
Gill, M.R.; Menon, J.U.; Jarman, P.J.; Owen, J.; Skaripa‐Koukelli, I.; Able, S.; Thomas, J.A.; Carlisle, R.; Vallis, K.A. (111)In‐
labelled polymeric nanoparticles incorporating a ruthenium‐based radiosensitizer for EGFR‐targeted combination therapy in
oesophageal cancer cells. Nanoscale 2018, 10, 10596–10608, doi:10.1039/c7nr09606b.

Pharmaceutics 2021, 13, 723

22 of 26

104. Sood, R.; Rositch, A.F.; Shakoor, D.; Ambinder, E.; Pool, K.‐L.; Pollack, E.; Mollura, D.J.; Mullen, L.A.; Harvey, S.C. Ultrasound
for Breast Cancer Detection Globally: A Systematic Review and
Meta‐Analysis. J. Glob. Oncol. 2019, 5, 1–17,
doi:10.1200/JGO.19.00127.
105. Polyak, K. Heterogeneity in breast cancer. J. Clin. Investig. 2011, 121, 3786–3788, doi:10.1172/JCI60534.
106. Hammond, M.E.H.; Hayes, D.F.; Dowsett, M.; Allred, D.C.; Hagerty, K.L.; Badve, S.; Fitzgibbons, P.L.; Francis, G.; Goldstein,
N.S.; Hayes, M.; et al. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations
for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. J. Clin. Oncol. 2010, 28, 2784–2795,
doi:10.1200/JCO.2009.25.6529.
107. Wolff, A.C.; Hammond, M.E.H.; Hicks, D.G.; Dowsett, M.; McShane, L.M.; Allison, K.H.; Allred, D.C.; Bartlett, J.M.S.; Bilous,
M.; Fitzgibbons, P.; et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American
Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch. Pathol. Lab. Med. 2014,
138, 241–256, doi:10.5858/arpa.2013‐0953‐SA.
108. Yanagawa, M.; Ikemot, K.; Kawauchi, S.; Furuya, T.; Yamamoto, S.; Oka, M.; Oga, A.; Nagashima, Y.; Sasaki, K. Luminal A and
luminal B (HER2 negative) subtypes of breast cancer consist of a mixture of tumors with different genotype. BMC Res. Notes
2012, 5, 376, doi:10.1186/1756‐0500‐5‐376.
109. Prado‐Vázquez, G.; Gámez‐Pozo, A.; Trilla‐Fuertes, L.; Arevalillo, J.M.; Zapater‐Moros, A.; Ferrer‐Gómez, M.; Díaz‐Almirón,
M.; López‐Vacas, R.; Navarro, H.; Maín, P.; et al. A novel approach to triple‐negative breast cancer molecular classification
reveals a luminal immune‐positive subgroup with good prognoses. Sci. Rep. 2019, 9, 1538, doi:10.1038/s41598‐018‐38364‐y.
110. Wang, J.; Xu, B. Targeted therapeutic options and future perspectives for HER2‐positive breast cancer. Signal Transduct. Target.
Ther. 2019, 4, 34, doi:10.1038/s41392‐019‐0069‐2.
111. Love, R.R.; Koroltchouk, V. Tamoxifen therapy in breast cancer control worldwide. Bull. World Health Organ. 1993, 71, 795–803.
112. Meiser, B.; Wong, W.K.T.; Peate, M.; Julian‐Reynier, C.; Kirk, J.; Mitchell, G. Motivators and barriers of tamoxifen use as risk‐
reducing medication amongst women at increased breast cancer risk: a systematic literature review. Hered. Cancer Clin. Pract.
2017, 15, 14, doi:10.1186/s13053‐017‐0075‐8.
113. Cuzick, J.; Sestak, I.; Bonanni, B.; Costantino, J.P.; Cummings, S.; DeCensi, A.; Dowsett, M.; Forbes, J.F.; Ford, L.; LaCroix, A.Z.;
et al. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta‐analysis of individual participant
data. Lancet (Lond. Engl. ) 2013, 381, 1827–1834, doi:10.1016/S0140‐6736(13)60140‐3.
114. Nazarali, S.A.; Narod, S.A. Tamoxifen for women at high risk of breast cancer. Breast Cancer 2014, 6, 29–36,
doi:10.2147/BCTT.S43763.
115. Narod, S.A. Tamoxifen Chemoprevention—End of the Road? JAMA Oncol. 2015, 1, 1033–1034, doi:10.1001/jamaoncol.2015.2247.
116. Fabian, C.J. The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer.
Int. J. Clin. Pract. 2007, 61, 2051–2063, doi:10.1111/j.1742‐1241.2007.01587.x.
117. Schneider, R.; Barakat, A.; Pippen, J.; Osborne, C. Aromatase inhibitors in the treatment of breast cancer in post‐menopausal
female patients: an update. Breast Cancer 2011, 3, 113–125, doi:10.2147/BCTT.S22905.
118. Anastrozole Approved for HR‐Positive Early Breast Cancer. Oncol. Times 2002, 24, doi:10.1097/01.COT.0000289547.21638.08.
119. Cohen, M.H.; Johnson, J.R.; Li, N.; Chen, G.; Pazdur, R. Approval summary: letrozole in the treatment of postmenopausal
women with advanced breast cancer. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 2002, 8, 665–669.
120. FDA Approval for Exemestane for Adjuvant Treatment for Early Breast Cancer in Postmenopausal Women. Oncol. Times 2005,
27, doi:10.1097/01.COT.0000291151.39520.67.
121. Tan, S.‐H.; Wolff, A.C. Luteinizing Hormone‐Releasing Hormone Agonists in Premenopausal Hormone Receptor–Positive
Breast Cancer. Clin. Breast Cancer 2007, 7, 455–464, doi:10.3816/CBC.2007.n.002.
122. Rocca, A.; Maltoni, R.; Bravaccini, S.; Donati, C.; Andreis, D. Clinical utility of fulvestrant in the treatment of breast cancer: a
report on the emerging clinical evidence. Cancer Manag. Res. 2018, 10, 3083–3099, doi:10.2147/CMAR.S137772.
123. Wakeling, A.E.; Dukes, M.; Bowler, J. A potent specific pure antiestrogen with clinical potential. Cancer Res. 1991, 51, 3867–3873.
124. Xu, H.; Yu, S.; Liu, Q.; Yuan, X.; Mani, S.; Pestell, R.G.; Wu, K. Recent advances of highly selective CDK4/6 inhibitors in breast
cancer. J. Hematol. Oncol. 2017, 10, 97, doi:10.1186/s13045‐017‐0467‐2.
125. Niu, Y.; Xu, J.; Sun, T. Cyclin‐Dependent Kinases 4/6 Inhibitors in Breast Cancer: Current Status, Resistance, and Combination
Strategies. J. Cancer 2019, 10, 5504–5517, doi:10.7150/jca.32628.
126. Li, X.; Dai, D.; Chen, B.; Tang, H.; Xie, X.; Wei, W. Efficacy of PI3K/AKT/mTOR pathway inhibitors for the treatment of advanced
solid
cancers: A literature‐based meta‐analysis of 46 randomised control trials. PLoS ONE 2018, 13, e0192464,
doi:10.1371/journal.pone.0192464.

Pharmaceutics 2021, 13, 723

23 of 26

127. Krop, I.E.; Mayer, I.A.; Ganju, V.; Dickler, M.; Johnston, S.; Morales, S.; Yardley, D.A.; Melichar, B.; Forero‐Torres, A.; Lee, S.C.;
et al. Pictilisib for oestrogen receptor‐positive, aromatase inhibitor‐resistant, advanced or metastatic breast cancer (FERGI): a
randomised, double‐blind, placebo‐controlled, phase 2 trial. Lancet Oncol. 2016, 17, 811–821, doi:10.1016/S1470‐2045(16)00106‐6.
128. Rodon, J.; Braña, I.; Siu, L.L.; De Jonge, M.J.; Homji, N.; Mills, D.; Di Tomaso, E.; Sarr, C.; Trandafir, L.; Massacesi, C.; et al. Phase
I dose‐escalation and ‐expansion study of buparlisib (BKM120), an oral pan‐Class I PI3K inhibitor, in patients with advanced
solid tumors. Investig. New Drugs 2014, 32, 670–681, doi:10.1007/s10637‐014‐0082‐9.
129. Folkes, A.J.; Ahmadi, K.; Alderton, W.K.; Alix, S.; Baker, S.J.; Box, G.; Chuckowree, I.S.; Clarke, P.A.; Depledge, P.; Eccles, S.A.;
et al. The identification of 2‐(1H‐indazol‐4‐yl)‐6‐(4‐methanesulfonyl‐piperazin‐1‐ylmethyl)‐4‐morpholin‐4‐yl‐thieno[3,2‐
d]pyrimidine (GDC‐0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J.
Med. Chem. 2008, 51, 5522–5532, doi:10.1021/jm800295d.
130. Sarker, D.; Ang, J.E.; Baird, R.; Kristeleit, R.; Shah, K.; Moreno, V.; Clarke, P.A.; Raynaud, F.I.; Levy, G.; Ware, J.A.; et al. First‐
in‐Human Phase I Study of Pictilisib (GDC‐0941), a Potent Pan{\textendash}Class I Phosphatidylinositol‐3‐Kinase (PI3K)
Inhibitor, in Patients with Advanced Solid Tumors. Clin. Cancer Res. 2015, 21, 77–86, doi:10.1158/1078‐0432.CCR‐14‐0947.
131. Shapiro, G.I.; Rodon, J.; Bedell, C.; Kwak, E.L.; Baselga, J.; Braña, I.; Pandya, S.S.; Scheffold, C.; Laird, A.D.; Nguyen, L.T.; et al.
Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan‐Class I PI3K Inhibitor, in
Patients with Advanced Solid Tumors. Clin. Cancer Res. 2014, 20, 233–245, doi:10.1158/1078‐0432.CCR‐13‐1777.
132. Blackwell, K.; Burris, H.; Gomez, P.; Lynn Henry, N.; Isakoff, S.; Campana, F.; Gao, L.; Jiang, J.; Macé, S.; Tolaney, S.M. Phase
I/II dose‐escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone‐
receptor‐positive and HER2‐negative metastatic breast cancer refractory to a non‐steroidal aromatase inhibitor. Breast Cancer
Res. Treat. 2015, 154, 287–297, doi:10.1007/s10549‐015‐3615‐9.
133. Albanell, J.; Baselga, J. Trastuzumab, a humanized anti‐HER2 monoclonal antibody, for the treatment of breast cancer. Drugs
Today 1999, 35, 931–946.
134. Saura, C.; Bendell, J.; Jerusalem, G.; Su, S.; Ru, Q.; De Buck, S.; Mills, D.; Ruquet, S.; Bosch, A.; Urruticoechea, A.; et al. Phase Ib
study of Buparlisib plus Trastuzumab in patients with HER2‐positive advanced or metastatic breast cancer that has
progressed on Trastuzumab‐based therapy. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 2014, 20, 1935–1945, doi:10.1158/1078‐
0432.CCR‐13‐1070.
135. Tolaney, S.; Burris, H.; Gartner, E.; Mayer, I.A.; Saura, C.; Maurer, M.; Ciruelos, E.; Garcia, A.A.; Campana, F.; Wu, B.; et al.
Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab‐
refractory HER2‐positive metastatic breast cancer. Breast Cancer Res. Treat. 2015, 149, 151–161, doi:10.1007/s10549‐014‐3248‐4.
136. Ishii, K.; Morii, N.; Yamashiro, H. Pertuzumab in the treatment of HER2‐positive breast cancer: an evidence‐based review of its
safety, efficacy, and place in therapy. Core Evid. 2019, 14, 51–70, doi:10.2147/CE.S217848.
137. Chan, A.; Delaloge, S.; Holmes, F.A.; Moy, B.; Iwata, H.; Harvey, V.J.; Robert, N.J.; Silovski, T.; Gokmen, E.; von Minckwitz, G.;
et al. Neratinib after trastuzumab‐based adjuvant therapy in patients with HER2‐positive breast cancer (ExteNET): a multicentre,
randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Oncol. 2016, 17, 367–377, doi:10.1016/S1470‐2045(15)00551‐3.
138. Mukai, H.; Saeki, T.; Aogi, K.; Naito, Y.; Matsubara, N.; Shigekawa, T.; Ueda, S.; Takashima, S.; Hara, F.; Yamashita, T.; et al.
Patritumab plus trastuzumab and paclitaxel in human epidermal growth factor receptor 2‐overexpressing metastatic breast
cancer. Cancer Sci. 2016, 107, 1465–1470, doi:10.1111/cas.13017.
139. Earl, H.M.; Hiller, L.; Dunn, J.A.; Blenkinsop, C.; Grybowicz, L.; Vallier, A.‐L.; Abraham, J.; Thomas, J.; Provenzano, E.; Hughes‐
Davies, L.; et al. Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and
cyclophosphamide, for women with HER2‐negative early breast cancer (ARTemis): an open‐label, randomised, phase 3 trial.
Lancet Oncol. 2015, 16, 656–666, doi:10.1016/S1470‐2045(15)70137‐3.
140. Verret, B.; Cortes, J.; Bachelot, T.; Andre, F.; Arnedos, M. Efficacy of PI3K inhibitors in advanced breast cancer. Ann. Oncol. : Off.
J. Eur. Soc. Med. Oncol. 2019, 30, x12–x20, doi:10.1093/annonc/mdz381.
141. Peddi, P.F.; Hurvitz, S.A. Ado‐trastuzumab emtansine (T‐DM1) in human epidermal growth factor receptor 2 (HER2)‐positive
metastatic breast cancer: latest evidence and clinical potential. Ther. Adv. Med. Oncol. 2014, 6, 202–209,
doi:10.1177/1758834014539183.
142. Modi, S.; Saura, C.; Yamashita, T.; Park, Y.H.; Kim, S.‐B.; Tamura, K.; Andre, F.; Iwata, H.; Ito, Y.; Tsurutani, J.; et al. Trastuzumab
Deruxtecan in Previously Treated HER2‐Positive Breast Cancer. N. Engl. J. Med. 2020, 382, 610–621, doi:10.1056/NEJMoa1914510.
143. Kim, R.; Keam, B.; Hahn, S.; Ock, C.‐Y.; Kim, M.; Kim, T.M.; Kim, D.‐W.; Heo, D.S. First‐line Pembrolizumab versus
Pembrolizumab Plus Chemotherapy Versus Chemotherapy Alone in Non‐small‐cell Lung Cancer: A Systematic Review and
Network Meta‐analysis. Clin. Lung Cancer 2019, 20, 331‐338.e4, doi:10.1016/j.cllc.2019.05.009.
144. Kang, C.; Syed, Y.Y. Atezolizumab (in Combination with Nab‐Paclitaxel): A Review in Advanced Triple‐Negative Breast Cancer.
Drugs 2020, 80, 601–607, doi:10.1007/s40265‐020‐01295‐y.

Pharmaceutics 2021, 13, 723

24 of 26

145. Huerta‐Reyes, M.; Maya‐Núñez, G.; Pérez‐Solis, M.A.; López‐Muñoz, E.; Guillén, N.; Olivo‐Marin, J.‐C.; Aguilar‐Rojas, A.
Treatment of Breast Cancer With Gonadotropin‐Releasing Hormone Analogs. Front. Oncol. 2019, 9, 943,
doi:10.3389/fonc.2019.00943.
146. Schally, A.V.; Engel, J.B.; Pinski, J.; Block, N.L. Chapter 73—LHRH Analogs. In Handbook of Biologically Active Peptides, 2nd ed.;
Academic Press: Boston, MA, USA, 2013; pp. 531–540. ISBN 978‐0‐12‐385095‐9.
147. Weir, H.M.; Bradbury, R.H.; Lawson, M.; Rabow, A.A.; Buttar, D.; Callis, R.J.; Curwen, J.O.; de Almeida, C.; Ballard, P.; Hulse,
M.; et al. AZD9496: an oral estrogen receptor inhibitor that blocks the growth of ER‐positive and ESR1‐mutant breast tumors
in preclinical models. Cancer Res. 2016, 76, 3307–3318, doi:10.1158/0008‐5472.CAN‐15‐2357.
148. Xu, S.; Yu, S.; Dong, D.; Lee, L.T.O. G Protein‐Coupled Estrogen Receptor: A Potential Therapeutic Target in Cancer. Front.
Endocrinol. 2019, 10, 725, doi:10.3389/fendo.2019.00725.
149. Lykkesfeldt, A.E.; Larsen, S.S.; Briand, P. Human breast cancer cell lines resistant to pure anti‐estrogens are sensitive to
tamoxifen treatment. Int. J. Cancer 1995, 61, 529–534, doi:10.1002/ijc.2910610417.
150. Osborne, C.K.; Coronado‐Heinsohn, E.B.; Hilsenbeck, S.G.; McCue, B.L.; Wakeling, A.E.; McClelland, R.A.; Manning, D.L.;
Nicholson, R.I. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast
cancer. J. Natl. Cancer Inst. 1995, 87, 746–750, doi:10.1093/jnci/87.10.746.
151. Dowsett, M.; Nicholson, R.I.; Pietras, R.J. Biological characteristics of the pure antiestrogen fulvestrant: overcoming endocrine
resistance. Breast Cancer Res. Treat. 2005, 93, S11, doi:10.1007/s10549‐005‐9037‐3.
152. Michaud, L.B.; Jones, K.L.; Buzdar, A.U. Combination endocrine therapy in the management of breast cancer. Oncologist 2001,
6, 538–546, doi:10.1634/theoncologist.6‐6‐538.
153. Bergh, J.; Jönsson, P.‐E.; Lidbrink, E.K.; Trudeau, M.; Eiermann, W.; Brattström, D.; Lindemann, J.P.O.; Wiklund, F.; Henriksson,
R. FACT: an open‐label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole
alone as first‐line therapy for patients with receptor‐positive postmenopausal breast cancer. J. Clin. Oncol.: Off. J. Am. Soc. Clin.
Oncol. 2012, 30, 1919–1925, doi:10.1200/JCO.2011.38.1095.
154. Mehta, R.S.; Barlow, W.E.; Albain, K.S.; Vandenberg, T.A.; Dakhil, S.R.; Tirumali, N.R.; Lew, D.L.; Hayes, D.F.; Gralow, J.R.;
Livingston, R.B.; et al. Combination Anastrozole and Fulvestrant in Metastatic Breast Cancer. N. Engl. J. Med. 2012, 367, 435–
444, doi:10.1056/NEJMoa1201622.
155. Johnston, S.R.; Kilburn, L.S.; Ellis, P.; Dodwell, D.; Cameron, D.; Hayward, L.; Im, Y.‐H.; Braybrooke, J.P.; Brunt, A.M.; Cheung,
K.‐L.; et al. Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non‐steroidal aromatase
inhibitors in postmenopausal patients with hormone‐receptor‐positive locally advanced or metastatic breast cancer (SoFEA): A
composite, multicent. Lancet Oncol. 2013, 14, 989–998, doi:10.1016/S1470‐2045(13)70322‐X.
156. Chen, X.; Xu, D.; Li, X.; Zhang, J.; Xu, W.; Hou, J.; Zhang, W.; Tang, J. Latest Overview of the Cyclin‐Dependent Kinases 4/6
Inhibitors in Breast Cancer: The Past, the Present and the Future. J. Cancer 2019, 10, 6608–6617, doi:10.7150/jca.33079.
157. Tan, A.R.; Yang, X.; Berman, A.; Zhai, S.; Sparreboom, A.; Parr, A.L.; Chow, C.; Brahim, J.S.; Steinberg, S.M.; Figg, W.D.; et al.
Phase I Trial of the Cyclin‐Dependent Kinase Inhibitor Flavopiridol in Combination with Docetaxel in Patients with Metastatic
Breast Cancer. Clin. Cancer Res. 2004, 10, 5038–5047, doi:10.1158/1078‐0432.CCR‐04‐0025.
158. Barroso‐Sousa, R.; Shapiro, G.I.; Tolaney, S.M. Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in
Breast Cancer. Breast Care 2016, 11, 167–173, doi:10.1159/000447284.
159. Cristofanilli, M.; Turner, N.C.; Bondarenko, I.; Ro, J.; Im, S.‐A.; Masuda, N.; Colleoni, M.; DeMichele, A.; Loi, S.; Verma, S.; et al.
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone‐receptor‐positive, HER2‐negative
metastatic breast cancer that progressed on previous endocrine therapy (PALOMA‐3): final analysis of the multicentre, double‐
blind, pha. Lancet Oncol. 2016, 17, 425–439, doi:10.1016/S1470‐2045(15)00613‐0.
160. Hortobagyi, G.N.; Stemmer, S.M.; Burris, H.A.; Yap, Y.‐S.; Sonke, G.S.; Paluch‐Shimon, S.; Campone, M.; Blackwell, K.L.; André,
F.; Winer, E.P.; et al. Ribociclib as First‐Line Therapy for HR‐Positive, Advanced Breast Cancer. New Engl. J. Med. 2016, 375,
1738–1748, doi:10.1056/NEJMoa1609709.
161. Finn, R.S.; Martin, M.; Rugo, H.S.; Jones, S.; Im, S.‐A.; Gelmon, K.; Harbeck, N.; Lipatov, O.N.; Walshe, J.M.; Moulder, S.; et al.
Palbociclib and Letrozole in Advanced Breast Cancer. New Engl. J. Med. 2016, 375, 1925–1936, doi:10.1056/NEJMoa1607303.
162. Liu, P.; Cheng, H.; Roberts, T.M.; Zhao, J.J. Targeting the phosphoinositide 3‐kinase pathway in cancer. Nat. Rev. Drug Discov.
2009, 8, 627–644, doi:10.1038/nrd2926.
163. Beser, A.R.; Tuzlali, S.; Guzey, D.; Dolek Guler, S.; Hacihanefioglu, S.; Dalay, N. HER‐2, TOP2A and chromosome 17 alterations
in breast cancer. Pathol. Oncol. Res. 2007, 13, 180–185, doi:10.1007/BF02893497.
164. Yarden, Y. Biology of HER2 and its importance in breast cancer. Oncology 2001, 61, 1–13, doi:10.1159/000055396.
165. Witton, C.J.; Reeves, J.R.; Going, J.J.; Cooke, T.G.; Bartlett, J.M.S. Expression of the HER1‐4 family of receptor tyrosine kinases
in breast cancer. J. Pathol. 2003, 200, 290–297, doi:10.1002/path.1370.

Pharmaceutics 2021, 13, 723

25 of 26

166. Cismowski, M. Tyrosine Kinase Inhibitors. In xPharm: The Comprehensive Pharmacology Reference; Elsevier: Amsterdam, The
Netherlands, 2007; pp. 1–4. ISBN 9780080552323.
167. Xuhong, J.‐C.; Qi, X.‐W.; Zhang, Y.; Jiang, J. Mechanism, safety and efficacy of three tyrosine kinase inhibitors lapatinib,
neratinib and pyrotinib in HER2‐positive breast cancer. Am. J. Cancer Res. 2019, 9, 2103–2119.
168. Guan, Z.; Xu, B.; DeSilvio, M.L.; Shen, Z.; Arpornwirat, W.; Tong, Z.; Lorvidhaya, V.; Jiang, Z.; Yang, J.; Makhson, A.; et al.
Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor
2‐overexpressing metastatic breast cancer. J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol. 2013, 31, 1947–1953,
doi:10.1200/JCO.2011.40.5241.
169. Chien, A.J.; Rugo, H.S. Tyrosine Kinase Inhibitors for Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast
Cancer: Is Personalizing Therapy Within Reach? J. Clin. Oncol. 2017, 35, 3089–3091, doi:10.1200/JCO.2017.73.5670.
170. Li, X.; Yang, C.; Wan, H.; Zhang, G.; Feng, J.; Zhang, L.; Chen, X.; Zhong, D.; Lou, L.; Tao, W.; et al. Discovery and development
of pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of
breast cancer. Eur. J. Pharm. Sci.: Off. J. Eur. Fed. Pharm. Sci. 2017, 110, 51–61, doi:10.1016/j.ejps.2017.01.021.
171. Hudis, C.A. Trastuzumab — Mechanism of Action and Use in Clinical Practice. N. Engl. J. Med. 2007, 357, 39–51,
doi:10.1056/NEJMra043186.
172. Adamczyk, A.; Niemiec, J.; Janecka, A.; Harazin‐Lechowska, A.; Ambicka, A.; Grela‐Wojewoda, A.; Domagała‐Haduch, M.;
Cedrych, I.; Majchrzyk, K.; Kruczak, A.; et al. Prognostic value of PIK3CA mutation status, PTEN and androgen receptor
expression for metastasis‐free survival in HER2‐positive breast cancer patients treated with trastuzumab in adjuvant setting.
Pol. J. Pathol.: Off. J. Pol. Soc. Pathol. 2015, 66, 133–141, doi:10.5114/pjp.2015.53009.
173. Loibl, S.; Gianni, L. HER2‐positive breast cancer. Lancet 2017, 389, 2415–2429, doi:10.1016/S0140‐6736(16)32417‐5.
174. Luo, C.; Zhong, X.; Wang, Z.; Wang, Y.; Wang, Y.; He, P.; Peng, Q.; Zheng, H. Prognostic nomogram for patients with non‐
metastatic HER2 positive breast cancer in a prospective cohort. Int. J. Biol. Mark. 2019, 34, 41–46, doi:10.1177/1724600818824786.
175. Adams, C.W.; Allison, D.E.; Flagella, K.; Presta, L.; Clarke, J.; Dybdal, N.; McKeever, K.; Sliwkowski, M.X. Humanization of a
recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunol.
Immunother. 2006, 55, 717–727, doi:10.1007/s00262‐005‐0058‐x.
176. Franklin, M.C.; Carey, K.D.; Vajdos, F.F.; Leahy, D.J.; de Vos, A.M.; Sliwkowski, M.X. Insights into ErbB signaling from the
structure of the ErbB2‐pertuzumab complex. Cancer Cell 2004, 5, 317–328, doi:10.1016/s1535‐6108(04)00083‐2.
177. Dawson, S.J.; Provenzano, E.; Caldas, C. Triple negative breast cancers: Clinical and prognostic implications. Eur. J. Cancer 2009,
45, 27–40, doi:10.1016/S0959‐8049(09)70013‐9.
178. Anders, C.; Carey, L.A. Understanding and treating triple‐negative breast cancer. Oncology 2008, 22, 1233–1243.
179. Liedtke, C.; Mazouni, C.; Hess, K.R.; André, F.; Tordai, A.; Mejia, J.A.; Symmans, W.F.; Gonzalez‐Angulo, A.M.; Hennessy, B.;
Green, M.; et al. Response to neoadjuvant therapy and long‐term survival in patients with triple‐negative breast cancer. J. Clin.
Oncol.: Off. J. Am. Soc. Clin. Oncol. 2008, 26, 1275–1281, doi:10.1200/JCO.2007.14.4147.
180. Lin, N.U.; Vanderplas, A.; Hughes, M.E.; Theriault, R.L.; Edge, S.B.; Wong, Y.‐N.; Blayney, D.W.; Niland, J.C.; Winer, E.P.;
Weeks, J.C. Clinicopathologic features, patterns of recurrence, and survival among women with triple‐negative breast cancer
in the National Comprehensive Cancer Network. Cancer 2012, 118, 5463–5472, doi:10.1002/cncr.27581.
181. Tong, C.W.S.; Wu, M.; Cho, W.C.S.; To, K.K.W. Recent Advances in the Treatment of Breast Cancer. Front. Oncol. 2018, 8, 227,
doi:10.3389/fonc.2018.00227.
182. Tutt, A.; Tovey, H.; Cheang, M.C.U.; Kernaghan, S.; Kilburn, L.; Gazinska, P.; Owen, J.; Abraham, J.; Barrett, S.; Barrett‐Lee, P.;
et al. Carboplatin in BRCA1/2‐mutated and triple‐negative breast cancer BRCAness subgroups: The TNT Trial. Nat. Med. 2018,
24, 628–637, doi:10.1038/s41591‐018‐0009‐7.
183. Bardia, A.; Mayer, I.; Vahdat, L.; Tolaney, S.; Isakoff, S.; Diamond, J.; O’Shaughnessy, J.; Moroose, R.; Santin, A.; Abramson, V.;
et al. Sacituzumab Govitecan‐hziy in Refractory Metastatic Triple‐Negative Breast Cancer. N. Engl. J. Med. 2019, 380, 741–751,
doi:10.1056/NEJMoa1814213.
184. Aschenbrenner, D.S. New Drug Approved for HER2‐positive Metastatic Breast Cancer. Am. J. Nurs. 2020, 120, 23.
185. Jeelani, S.; Reddy, R.C.J.; Maheswaran, T.; Asokan, G.S.; Dany, A.; Anand, B. Theranostics: A treasured tailor for tomorrow. J.
Pharm. Bioallied Sci. 2014, 6, S6–S8, doi:10.4103/0975‐7406.137249.
186. Shah, J. V; Gonda, A.; Pemmaraju, R.; Subash, A.; Bobadilla Mendez, C.; Berger, M.; Zhao, X.; He, S.; Riman, R.E.; Tan, M.C.; et
al. Shortwave Infrared‐Emitting Theranostics for Breast Cancer Therapy Response Monitoring. Front. Mol. Biosci. 2020, 7, 287,
doi:10.3389/fmolb.2020.569415.
187. Bartelink, I.H.; Jones, E.F.; Shahidi‐Latham, S.K.; Lee, P.R.E.; Zheng, Y.; Vicini, P.; van ’t Veer, L.; Wolf, D.; Iagaru, A.; Kroetz,
D.L.; et al. Tumor Drug Penetration Measurements Could Be the Neglected Piece of the Personalized Cancer Treatment Puzzle.
Clin. Pharmacol. Ther. 2019, 106, 148–163, doi:10.1002/cpt.1211.

Pharmaceutics 2021, 13, 723

26 of 26

188. Tannock, I.F. Conventional cancer therapy: promise broken or promise delayed? Lancet 1998, 351, SII9–SII16, doi:10.1016/s0140‐
6736(98)90327‐0.
189. Ahn, B.‐C. Personalized Medicine Based on Theranostic Radioiodine Molecular Imaging for Differentiated Thyroid Cancer.
Biomed. Res. Int. 2016, 2016, 1680464, doi:10.1155/2016/1680464.
190. Thakur, V.; Kutty, R.V. Recent advances in nanotheranostics for triple negative breast cancer treatment. J. Exp. Clin. Cancer Res.
2019, 38, 430, doi:10.1186/s13046‐019‐1443‐1.
191. Engebraaten, O.; Vollan, H.K.M.; Børresen‐Dale, A.‐L. Triple‐negative breast cancer and the need for new therapeutic targets.
Am. J. Pathol. 2013, 183, 1064–1074, doi:10.1016/j.ajpath.2013.05.033.
192. Sumer, B.; Gao, J. Theranostic nanomedicine for cancer. Nanomedicine 2008, 3, 137–140, doi:10.2217/17435889.3.2.137.
193. Gregoriou, Y.; Gregoriou, G.; Yilmaz, V.; Kapnisis, K.; Prokopi, M.; Anayiotos, A.; Strati, K.; Dietis, N.; Constantinou, A.I.;
Andreou, C. Resveratrol loaded polymeric micelles for theranostic targeting of breast cancer cells. Nanotheranostics 2020, 5, 113–
124, doi:10.7150/ntno.51955.
194. Wang, Y.; Wang, Y.; Chen, G.; Li, Y.; Xu, W.; Gong, S. Quantum‐Dot‐Based Theranostic Micelles Conjugated with an Anti‐EGFR
Nanobody for
Triple‐Negative Breast Cancer Therapy. ACS Appl. Mater. Interfaces 2017, 9, 30297–30305,
doi:10.1021/acsami.7b05654.
195. Parhi, P.; Sahoo, S.K. Trastuzumab guided nanotheranostics: A lipid based multifunctional nanoformulation for targeted drug
delivery and imaging in breast cancer therapy. J. Colloid Interface Sci. 2015, 451, 198–211, doi:10.1016/j.jcis.2015.03.049.
196. Hafner, S.; Raabe, M.; Wu, Y.; Wang, T.; Zuo, Z.; Rasche, V.; Syrovets, T.; Weil, T.; Simmet, T. High‐Contrast Magnetic Resonance
Imaging and Efficient Delivery of an Albumin Nanotheranostic in Triple‐Negative Breast Cancer Xenografts. Adv. Ther. 2019, 2,
1900084, doi:10.1002/adtp.201900084.
197. Li, J.; Cai, P.; Shalviri, A.; Henderson, J.T.; He, C.; Foltz, W.D.; Prasad, P.; Brodersen, P.M.; Chen, Y.; DaCosta, R.; et al. A
Multifunctional Polymeric Nanotheranostic System Delivers Doxorubicin and Imaging Agents across the Blood–Brain Barrier
Targeting Brain Metastases of Breast Cancer. ACS Nano 2014, 8, 9925–9940, doi:10.1021/nn501069c.
198. Li, L.; Fu, J.; Wang, X.; Chen, Q.; Zhang, W.; Cao, Y.; Ran, H. Biomimetic “Nanoplatelets” as a Targeted Drug Delivery Platform
for Breast Cancer Theranostics. ACS Appl. Mater. Interfaces 2021, 13, 3605–3621, doi:10.1021/acsami.0c19259.
199. Dong, Q.; Yang, H.; Wan, C.; Zheng, D.; Zhou, Z.; Xie, S.; Xu, L.; Du, J.; Li, F. Her2‐Functionalized Gold‐Nanoshelled Magnetic
Hybrid Nanoparticles: a Theranostic Agent for Dual‐Modal Imaging and Photothermal Therapy of Breast Cancer. Nanoscale Res.
Lett. 2019, 14, 235, doi:10.1186/s11671‐019‐3053‐4.
200. Brabec, V.; Nováková, O. DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity. Coordination Chem.
Rev. 2006, 9, 111–122, doi:10.1016/j.drup.2006.05.002.
201. Tan, L.; Shen, J.; Liu, J.; Zeng, L.; Jin, L.; Weng, C. Spectral characteristics, DNA‐binding and cytotoxicity of two functional Ru
(II) mixed‐ligand complexes. Dalton Trans. 2012, 41, 4575–4587, doi:10.1039/C2DT12402E.
202. Shen, J.; Kim, H.‐C.; Wolfram, J.; Mu, C.; Zhang, W.; Liu, H.; Xie, Y.; Mai, J.; Zhang, H.; Li, Z.; et al. A Liposome Encapsulated
Ruthenium Polypyridine Complex as a Theranostic Platform for Triple‐Negative Breast Cancer. Nano Lett. 2017, 17, 2913–2920,
doi:10.1021/acs.nanolett.7b00132.
203. Zheng, D.; Wan, C.; Yang, H.; Xu, L.; Dong, Q.; Du, C.; Du, J.; Li, F. Her2‐Targeted Multifunctional Nano‐Theranostic Platform
Mediates Tumor Microenvironment Remodeling and Immune Activation for Breast Cancer Treatment. Int. J. Nanomed. 2020, 15,
10007–10028, doi:10.2147/IJN.S271213.
204. Tang, L.; Yang, X.; Yin, Q.; Cai, K.; Wang, H.; Chaudhury, I.; Yao, C.; Zhou, Q.; Kwon, M.; Hartman, J.A.; et al. Investigating the
optimal size of anticancer nanomedicine. Proc. Natl. Acad. Sci. USA 2014, 111, 15344–15349, doi:10.1073/pnas.1411499111.
205. Liu, R.; Xiao, W.; Hu, C.; Xie, R.; Gao, H. Theranostic size‐reducible and no donor conjugated gold nanocluster fabricated
hyaluronic acid nanoparticle with optimal size for combinational treatment of breast cancer and lung metastasis. J. Control.
Release: Off. J. Control. Release Soc. 2018, 278, 127–139, doi:10.1016/j.jconrel.2018.04.005.
206. Liu, R.; Hu, C.; Yang, Y.; Zhang, J.; Gao, H. Theranostic nanoparticles with tumor‐specific enzyme‐triggered size reduction and
drug release to perform photothermal therapy for breast cancer treatment. Acta Pharm. Sin. B 2019, 9, 410–420,
doi:10.1016/j.apsb.2018.09.001.
207. Burke, A.R.; Singh, R.N.; Carroll, D.L.; Wood, J.C.S.; D’Agostino, R.B.; Ajayan, P.M.; Torti, F.M.; Torti, S. V The resistance of
breast cancer stem cells to conventional hyperthermia and their sensitivity to nanoparticle‐mediated photothermal therapy.
Biomaterials 2012, 33, 2961–2970, doi:10.1016/j.biomaterials.2011.12.052.
208. Wu, Y.; Wang, H.; Gao, F.; Xu, Z.; Dai, F.; Liu, W. An Injectable Supramolecular Polymer Nanocomposite Hydrogel for
Prevention of Breast Cancer Recurrence with Theranostic and Mammoplastic Functions. Adv. Funct. Mater. 2018, 28, 1801000,
doi:10.1002/adfm.201801000.

